Spenser Lin No Comments

Healthcare News, Deals, and Investments Update August 24th, 2026

LECO_Weekly-Healthcare-News_8-24-2026Download

Healthcare Weekly News and Deals

  1. Francisco Partners to take Weave Communications (NYSE: WEAV) private for $650 million in an all-cash deal at $7.40 per share. The price is a 34% premium to Weave’s Monday closing price, and the company will delist after going public in 2021. The sponsor is buying a vertical platform serving independent medical, dental, optometry and veterinary practices, a customer base most software companies overlook. Weave generated $239 million of fiscal 2025 revenue, up 17%, and $65.5 million in the first quarter of fiscal 2026, also up 17%, yet its market value sits well below the $1.4 billion peak. Francisco Partners raised more than $75 billion and previously bought AdvancedMD for $1.125 billion. (Link)
  2. Universal Health Services (NYSE: UHS) has closed its $835 million debt-financed acquisition of virtual behavioral care provider Talkspace (NASD: TALK). The transaction valued Talkspace at $5.25 per share and was financed with debt. Talkspace keeps its brand and organizational structure, with CEO Jon Cohen reporting directly to UHS President and CEO Marc Miller. The target reported $229 million in revenue, $4.8 million in net income and $15.8 million in adjusted EBITDA in 2025, and runs a virtual network of more than 6,000 behavioral health professionals. Behavioral health already generated about 43% of the buyer’s $17.4 billion 2025 revenue, and UHS expects the deal to be slightly accretive to adjusted net income in the first year after closing. (Link)
  3. Thoma Bravo has to take Accelerant (NYSE: ARX) private at $20.25 per share in an all-cash deal valuing the specialty insurance risk exchange above $4 billion, with existing backer Altamont Capital Partners rolling over. The offer is a 49% premium to Accelerant’s closing price on 12 August 2026. Altamont Capital Partners, which controls around 82% of voting rights, supports the deal, and Altamont and the founders intend to keep an equity interest alongside Thoma Bravo. Thoma Bravo has committed equity, so completion does not depend on additional financing, and shareholders receive a 6% annual ticking fee if insurance regulatory approvals delay closing. Senior partner A.J. Rohde tied the thesis to MGA market growth. (Link)
  4. BioMarin (NASD: BMRN) to acquire Alesta Therapeutics for $275 million BioMarin Pharmaceutical has agreed to acquire Alesta Therapeutics to gain ALE1, a clinical-stage oral small molecule for hypophosphatasia. BioMarin will pay $275 million upfront and up to $215 million in development and regulatory milestones. Alesta will spin out all non-ALE1 assets prior to closing. ALE1 is being evaluated in a Phase 1/2a trial and has the potential to become the first oral therapy for the rare genetic bone disease. Closing is expected this quarter. (Link)
  5. Cityblock Health has signed an all-stock agreement to acquire Homeward Health and separately raised a $116 million Series E led by General Catalyst. Financial details of the all-stock acquisition were not disclosed. The $116 million Series E was led by General Catalyst and takes total capital raised past $900 million, against a $400 million 2021 round that set a roughly $5.7 billion valuation. The company says it is not focused on an exit at this time. Cityblock serves almost 200,000 members at $2.2 billion of annualized revenue, up 77% year over year, and the two businesses together will serve nearly 250,000 people. (Link)
  6. R1 to acquire Humata Health, the AI prior authorization company, to extend its Phare Operating System into payer-provider authorization workflows. Pricing was not disclosed and both parties are private. The investment case is denial prevention: prior authorization is a top-three driver of denials, and a KFF survey found one-third of insured adults call it the biggest burden in accessing care. Humata’s agentic workflows match payer policy, build AI-driven clinical bundles and manage requests to final approval, delivering up to a 96% first-pass approval rate while cutting write-offs by 30%, rescheduled appointments by 83% and staff touches by 45%. R1 folds the capability into Phare Intelligence and Payer Atlas and uses it to sell adjacent modules. (Link)
  7. Goldman Sachs Asset Management-backed Advanced Recovery Systems has acquired Promises Behavioral Health from Assured Healthcare Partners. Terms were not disclosed. Promises was previously backed by Assured Healthcare Partners, which converted its debt into equity in late 2021, after BlueMountain Capital Management bought the assets of bankrupt Elements Behavioral Health in 2018. Combined, the company operates 24 facilities in 14 states across medical detox, inpatient, residential and outpatient services. Goldman halted an auction of Advanced Recovery Systems in January, and addiction treatment dealmaking has fallen sharply, with six closings in the first half of 2026 against 19 a year earlier.(Link)
  8. General Catalyst-backed Radial has acquired TMS Health Partners, the MSO behind Mindful Health Solutions, delivering an exit for previous backer Aisling Capital. Terms were not disclosed. Radial is less than a year into its holding period with General Catalyst and has multiplied its clinical footprint with a single transaction. The combination brings Radial to 27 clinics across seven states, most of them from Mindful Health Solutions. The deal also caps a quick turnaround for Aisling Capital. Radial supports clinics with drug and device procurement, billing and RadialOS, an AI clinical decision support tools. (Link)
  9. Flexpoint sells ArtesRx to Linden Capital Partners Flexpoint Ford has completed the sale of ArtesRx, its specialty behavioral health pharmacy platform, to Linden Capital Partners. Formed in 2023, ArtesRx focuses on complex medication regimens for patients with serious mental illness, substance use disorders, and intellectual and developmental disabilities. Under Flexpoint ownership the platform expanded from three pharmacies in a single state to 16 locations across 15 states through organic growth and targeted M&A. Financial terms were not disclosed. (Link)
  10. BPOC partners with Master Medical Equipment and ReNew Biomedical BPOC has made strategic investments in Master Medical Equipment and ReNew Biomedical, sister companies that provide capital equipment distribution, rental, repair and preventative maintenance services to the pre-hospital and post-acute markets. The Jackson, Tennessee-based businesses offer new and refurbished equipment along with biomedical service across a national footprint. Founder and CEO Mark Taylor will continue to lead the companies. Financial terms were not disclosed. (Link)
  11. Truehelm and QHP Capital-backed InformedDNA has divested its Genetic Testing Utilization Management business unit to Zyter, a subsidiary of global technology company Infinite. Terms were not disclosed. InformedDNA is a portfolio company of Truehelm and QHP Capital, and the sale follows the May 2026 divestiture of its Payment Integrity business unit. The sponsors are concentrating remaining capital behind DNAimpact, InformedDNA’s precision health platform, rather than running three businesses at once. The divested unit pairs genetics-trained specialists with evidence-based review for health plans, a capability that grows more valuable as genetic test volume and complexity compound. Truehelm partner and board member Conor Green described the process as sharpening InformedDNA’s focus. (Link)
  12. U.S. Oral Surgery Management, backed by Oak Hill Capital, has partnered with Cottonwood Oral & Maxillofacial Surgery of Albuquerque in its third New Mexico transaction. Terms were not disclosed and both parties are private. USOSM is a management services organization that works exclusively with oral and maxillofacial surgeons and now spans 31 states. The specialist-only mandate is the differentiator against general dental consolidators, and single-practice tuck-ins remain the primary growth mechanism. CEO Doug Drew pointed to clinical reputation, patient care and safety as the selection criteria for the practice. USOSM provides operational, financial and administrative support to surgeons alongside wealth creation. (Link)
  13. Integrated Dermatology has entered the Kentucky market through a partnership with Knuckles Dermatology, which now operates as Integrated Dermatology of Kentucky. Terms were not disclosed and both parties are private. The partnership took effect August 18, 2026 and covers patients in Corbin, Richmond and surrounding southeastern Kentucky communities. Dr. Knuckles continues to practice, and two board-certified family nurse practitioners, Lauren Hayes and Jordan Patterson, join to expand provider capacity. Established in 2004, Integrated Dermatology operates in nearly 30 states and offers dermatologists profit-sharing and full clinical autonomy while handling operational and administrative work centrally.(Link)
  14. Concentra (NYSE: CON) has completed the acquisition of four Minnesota Occupational Health medical centers in the Twin Cities, taking its statewide network to 10 sites. Terms were not disclosed. The four acquired centers sit in Coon Rapids, Eagan, St. Paul Midway and Shakopee, and began operating as Concentra on August 17. Concentra has served Minnesota since 2018 and will now run 10 medical centers across the state. The buyer also plans significant investment in the St. Paul Midway center to make it a regional flagship. The economics rest on density and employer cross-selling across injury care, physical therapy, drug testing and DOT exams. (Link)
  15. Momentum Health Partners has expanded its investment in Desert Pain Specialists, the Rancho Mirage, California interventional pain management practice it first backed in 2023. The amount was not disclosed. The Phoenix-based platform deployed additional capital into Desert Pain Specialists following the acquisition and integration of Dr. Roland Reinhart’s pain management practice. The new capital funds physician recruitment, service line expansion and operational growth across California’s Coachella Valley, where the practice has posted growth in new patient volumes since integrating. Partner Ryan Harper framed the follow-on as confidence in the team. Momentum invests across autism therapy, developmental therapies, behavioral health and specialty ambulatory care. (Link)
  16. SEVA has made a growth equity investment in healthcare price transparency company Serif Health, the first outside institutional capital the San Francisco business since 2020 launch. Terms were not disclosed. The round is Serif Health’s first outside institutional capital since it launched in 2020, and SEVA founder and managing partner Shalin Mehta joins the board. Serif cleans, validates and standardises pricing data from hundreds of payers and thousands of hospitals through its Signal platform, used by more than 250 organisations to benchmark rates, evaluate networks and track market dynamics. Proceeds accelerate sales and expand a pipeline of product features and data APIs, following the 2026 launch of Signal Ask, a plain-language query tool. (Link)
  17. Providence Equity Partners to acquire a majority stake in CheckedUp, with Varsity Healthcare Partners joining as strategic minority. Terms were not disclosed. Providence is acquiring alongside the co-founders, who continue to lead the company, and Varsity Healthcare Partners as a healthcare services-focused minority investor. CheckedUp reaches >17,000 specialty healthcare providers and 15 million patients through waiting-room televisions and interactive exam-room wallboards, and works with most of the top 40 pharmaceutical manufacturers. Providence is underwriting this as a digital out-of-home media asset, consistent with prior positions in OUTFRONT Media, DoubleVerify and Smartly.io. (Link)
  18. Cypress Ridge Capital-backed Cresso Health has partnered with Slate Financial, the Southwest Medicare and health insurance distributor. Terms were not disclosed. Cresso Health is backed by New York-based healthcare investor Cypress Ridge Capital. The logic is distribution roll-up economics. Slate gains access to Cresso’s carrier relationships, distribution infrastructure, proprietary marketing and lead-generation tools and compliance toolkit, while Cresso extends its field presence. CEO Frank Pistone described the goal as an omni-channel, multi-product platform serving the senior market. Cypress Ridge invests exclusively in healthcare with a thematic, growth-oriented approach. (Link)
  19. Rockmont Partners has exited RepScrubs, the automated scrubs dispensing platform, with THL named as acquirer in Healthcare DealHub’s headline. Terms were not disclosed. Healthcare DealHub titles the transaction as THL acquiring RepScrubs from Rockmont Partners, while the deal note itself describes the buyer as undisclosed. Rockmont led a secondary purchase in the business in 2024, making this a short hold. RepScrubs runs an automated scrubs dispensing platform that manages vendor credentialing and enforces policy compliance for perioperative vendors at hospitals and surgery centers. The asset sits in digital and health technology, which has recorded 289 tracked deals year to date. (Link)
  20. Berks Community Health Center to merge with Lancaster-based Union Community Care, a distress-driven nonprofit combination pending regulatory approval. No purchase price applies. Board vice chair Missy Orlando named two financial triggers, starting with a sharp drop in federal Medicaid funding from January that could cost roughly 100,000 Berks County residents their benefits. The center has also struggled to collect patient payments and lost several providers over the past year. Union Community Care operates 25 locations across Lancaster, Lebanon and Chester counties, covering family medicine, urgent care, dental, school-based care, behavioral health and pharmacy. (Link)
  21. Mitsui Chemicals (Tokyo: 4183) has completed its acquisition of Utah-based dental products maker Ultradent Products, making it a wholly owned subsidiary alongside existing dental unit Kulzer. The deal closed on August 14, ahead of the September 2026 schedule, after competition and investment approvals came through early. Mitsui is making oral care the third earnings pillar of its Life & Healthcare Solutions segment and targeting the number two position in global dental materials. The company expects more than $40 million in annual synergy by fiscal 2030. Integration moves the oral care global headquarters to the United States, with Ultradent CEO Dirk Jeffs also taking over as Kulzer CEO while Kulzer’s Chris Holden becomes Chief Strategy and Integration Officer of MC Dental Holdings America.(Link)
  22. Osage Venture Partners-backed Curavit Clinical Research has acquired the CRO assets of Lindus Health, which is shifting to its own therapeutic pipeline as Lindus Therapeutics. Terms were not disclosed. The transaction follows Lindus shifting focus to developing its own pipeline of therapeutic assets. What Curavit bought is European delivery capability, not scale for its own sake: the combined business can now run decentralized, hybrid and traditional trials across North America and Europe under one operational partner. Nate Lentz, managing partner at Osage Venture Partners and a Curavit board member, tied the thesis to sponsors needing more flexible, technology-enabled approaches to generating clinical evidence. CEO Joel Morse positioned the platform against both regional niche CROs and legacy providers. (Link)

Venture Deals and Other

  1. 8VC and Town Hall Ventures have led a $53 million Series D in Hopscotch Primary Care. 8VC and Town Hall Ventures led the round, with existing investors aMoon Fund, Citi Impact Fund, Alumni Ventures and K2 HealthVentures participating and new investors including the Autism Impact Fund, Kleiner Perkins chairman John Doerr, Heritage Provider Network founder Dr. Richard Merkin and the Leon Levine Foundation. Founded in 2021, Hopscotch serves more than 15,000 patients across the rural Southeast, concentrated in western North Carolina. Investors have hard numbers to point at: a Net Promoter Score of 89, patient retention above 90%, medical loss ratio improvement of more than 25 percentage points over two years and profitable operations in western North Carolina. (Link)
  2. Section 32, Thiel Bio, Founders Fund, Breyer Capital, Blue Venture Fund and JSL Health Capital have funded Network Bio’s $50 million launch alongside an NVIDIA partnership. Network Bio, a Palo Alto company building AI models trained on human biological data, launched on August 19 with $50 million from investors including Section 32, Thiel Bio, Founders Fund, Breyer Capital, Blue Venture Fund and JSL Health Capital. The money funds a research network with Mass General Brigham, the University of Pennsylvania and the University of Colorado Anschutz, supplying tissue and blood samples paired with longitudinal clinical outcomes across immunology, metabolic, cardiovascular and autoimmune disease. Investors are paying for exclusive data access rather than a clinical asset. The launch came with an NVIDIA partnership to scale the models. (Link)
  3. InnovaHealth Partners led Channel Medsystems’ Series C to $30 million, backing the commercial expansion of the Cerene endometrial cryotherapy platform. The Berkeley medical technology company has reached $30 million in an ongoing Series C led by InnovaHealth Partners. InnovaHealth has backed Channel Medsystems since 2021. Proceeds fund commercial organization expansion, physician and patient awareness, professional education and training, clinical evidence generation and market development infrastructure. The raise follows a commercial relaunch of the platform. Founder and Managing Partner Mortimer Berkowitz III pointed to unmet need in women’s health backed by clinical evidence and an experienced leadership team. (Link)
  4. MaxQ Medical raises $31.5 million Series A backed by Olympus MaxQ Medical has closed a $31.5 million Series A led by Atlantic Blue Ventures, S3 Ventures and Olympus Innovation Ventures, with participation from Hillside Capital. The financing advances the company’s transurethral imaging-and-therapy platform for prostate disease, the first spinout from Orchard Ultrasound Innovation. The system combines real-time imaging with tissue-selective therapy in a single outpatient procedure, initially targeting BPH with planned expansion into focal therapy for prostate cancer. Proceeds support clinical program advancement and team expansion. (Link)
  5. Leal Therapeutics announces $30 million Series A extension Leal Therapeutics has completed a $30 million second close of its Series A, adding Eli Lilly as a new investor alongside existing backers OrbiMed, Newpath Partners, Euclidean Capital, SV Health Investors’ Dementia Discovery Fund and others. Proceeds will advance LTX-001, a first-in-class brain-penetrant oral GLS1 inhibitor, through initial readout of its newly initiated Phase 1b/2a trial in schizophrenia, and progress LTX-002 through additional dosing cohorts in an ongoing Phase 1/2 ALS study. (Link)
  6. Werewolf Therapeutics and Ambros Therapeutics announce merger and concurrent $150 million private placement Werewolf Therapeutics (Nasdaq: HOWL) and Ambros Therapeutics have entered an all-stock merger agreement accompanied by an oversubscribed $150 million private placement co-led by RA Capital and Janus Henderson. The combined company, to operate as Ambros Therapeutics and trade as AMBX, will advance neridronate in the pivotal CRPS-RISE Phase 3 trial for Complex Regional Pain Syndrome Type 1. Capital is expected to fund operations through Phase 3 topline results, planned NDA submission and into the first half of 2029. (Link)
  7. Gossamer Bio announces up to $250 million structured private placement Gossamer Bio has arranged a structured private placement of up to $250 million, including $150 million of committed capital, to fund development of seralutinib through potential FDA approval. The financing extends runway for late-stage clinical and regulatory activities surrounding the company’s lead pulmonary arterial hypertension program. (Link)
  8. Biotechnology investor Bob Nelsen has led a $20 million round in Astromech, joined by Peak 6, NeoGenesis Capital, Builders VC and CAZ Investments, lifting the Colossal Biosciences spinout to a $3.8 billion valuation. The round was led by Bob Nelsen with participation from Peak 6, NeoGenesis Capital, Builders VC and CAZ Investments, bringing total capital raised to $60 million. The valuation is unusual relative to check size, and what investors are buying is founder pedigree and a data position rather than near-term revenue. Astromech was co-founded by Ben Lamm and geneticist George Church, spun out of Colossal Biosciences, and uses 3.8 billion years of evolutionary history as a primary training signal. Longevity is the proving ground, with 46 longevity-associated genes mapped so far. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update August 10th, 2026

LECO_Weekly-Healthcare-News_8-10-2026Download

Healthcare Weekly News and Deals

  1. Hinge Health, Inc. (NYSE: HNGE) has signed a definitive agreement to acquire virtual-first digestive care provider Cylinder Health, Inc. for $105 million in cash. Hinge Health (NYSE: HNGE) is deploying $105 million of cash to enter gastrointestinal care, a category it sizes at $135 billion of annual U.S. medical spend affecting roughly one in four adults. Cylinder brings nearly 100 clients across two million lives, relationships with two of the three largest PBMs and three of the top five health plans by self-insured share, and more than 150,000 patients treated with a clinically validated ROI. The rationale is cross-sell economics: Hinge cites high comorbidity with its existing MSK and migraine populations. An integrated GI program launches in 2027; closing is expected in the third quarter of 2026. (Link)
  2. KKR has agreed to acquire Integer Holdings Corporation (NYSE: ITGR), the Plano, Texas-based medical device contract development and manufacturing organization, in an all-cash take-private valuing the company at an enterprise value of approximately $5.7 billion. KKR is paying $127.00 per share in cash for Integer Holdings (NYSE: ITGR), a 51.8% premium to Integer’s April 29, 2026 close and 28.8% over its 30-day VWAP as of July 31, 2026. The deal follows a board-led strategic review launched in April and is financed with equity from KKR-managed funds plus committed debt, with no financing contingency. KKR, which reported $796 billion of assets under management at quarter end, deepens a healthcare book that already includes the 2018 Envision take-private, and plans to establish an employee ownership program at Integer. Closing is expected by year-end 2026 and Integer will delist from the NYSE. (Link)
  3. Teleflex Incorporated (NYSE: TFX) has completed the divestiture of its OEM business to private equity firms Montagu and Kohlberg for $1.5 billion in cash, with the unit relaunched as Ingenyx. Montagu and Kohlberg have closed their $1.5 billion all-cash purchase of Teleflex’s (NYSE: TFX) contract manufacturing arm, carved out via Lotus US Bidco Inc. and rebranded Ingenyx. Teleflex estimates approximately $1.25 billion in after-tax proceeds and will apply them to $800 million of debt reduction and completion of a $1 billion share repurchase authorization. The sale was first announced in December 2025 alongside the Acute Care unit at $2.03 billion of combined value. For Teleflex, the exit concentrates the portfolio on Vascular Access, Interventional and Surgical; for the sponsors, it delivers a standalone medtech CDMO platform. (Link)
  4. Nordic Capital has agreed to carve out BWX Technologies, Inc.’s (NYSE: BWXT) medical business, including BWXT Medical and Kinectrics’ stable medical isotopes unit, in a transaction valued at up to $800 million. Nordic Capital, which manages roughly EUR 39 billion and runs a dedicated healthcare franchise, is acquiring BWXT’s (NYSE: BWXT) radiopharmaceutical platform in a carve-out valued at up to $800 million. BWXT has roughly tripled the unit’s revenue since buying it in 2018 and will retain a meaningful minority stake, allowing it to redeploy capital toward nuclear national security and commercial nuclear power. Partner Christian Hedegaard framed radiopharmaceuticals as sitting at the intersection of Nordic’s pharmaceutical and life sciences track record. The transaction is subject to customary regulatory approvals and is expected to close by the end of 2026. (Link)
  5. iRhythm Technologies, Inc. (NASD: IRTC) has agreed to acquire San Jose-based wearable biosensor company VitalConnect for $287.5 million, comprising $237.5 million in cash and approximately $50 million in iRhythm stock. iRhythm (NASDAQ: IRTC) is paying $287.5 million for VitalConnect, a private FDA-cleared biosensor platform running at an approximately $65 million annual revenue run rate, in a move that pushes iRhythm deeper into mobile cardiac telemetry. The deal was disclosed alongside 2Q26 results showing 20.1% year-over-year revenue growth and a $50 million patent settlement with Baxter. BTIG’s Marie Thibault called the deal surprising and expects mixed investor reaction, flagging concerns it could mask an MCT slowdown while noting the timing likely reflects VitalConnect’s capital needs. Management expects revenue contribution from 2027; closing is targeted by year-end. (Link)
  6. Jazz Pharmaceuticals (NASD:JAZZ) to acquire Actio Biosciences for $820 million upfront plus up to $500 million in milestones Jazz Pharmaceuticals (NASDAQ: JAZZ) has agreed to acquire privately held Actio Biosciences for $820 million in cash upfront and up to $500 million in contingent payments. The deal adds ABS-1230, a clinical-stage precision therapy targeting KCNT1+ epilepsy, a rare and severe developmental epileptic encephalopathy with no FDA-approved treatments. Jazz will also take a minority stake in a new spin-out company focused on other genetic rare neurological diseases. Closing is expected in the fourth quarter of 2026. (Link)
  7. Tarsus Pharmaceuticals (NASD:TARS) to acquire Alkeus Pharmaceuticals for approximately $450 million upfront plus up to $350 million in milestones Tarsus Pharmaceuticals (NASDAQ: TARS) has entered a definitive agreement to acquire Alkeus Pharmaceuticals, adding gildeuretinol (ALK-001), a Phase 3 oral investigational therapy for Stargardt disease. Consideration consists of roughly $270 million in cash and $180 million in Tarsus stock, plus up to $350 million in regulatory and commercial milestones and low single-digit royalties. The asset has Breakthrough Therapy, Orphan Drug and Rare Pediatric Disease designations; Phase 3 NORTHSTAR topline data are expected in the second half of 2029. Closing is anticipated in 2026. (Link)
  8. Supernus Pharmaceuticals (NASD:SUPN) and Indivior Pharmaceuticals (NASD:INDV) to merge in all-stock transaction, creating a diversified CNS company Supernus Pharmaceuticals (NASDAQ: SUPN) and Indivior Pharmaceuticals (NASDAQ: INDV) have agreed to combine in a tax-free all-stock merger of equals. The combined company, to be named Supernus, Inc., is expected to generate approximately $2.2 billion in pro forma annual revenue and $125 million in annual cost synergies. Indivior stockholders will receive a $1 billion special cash dividend immediately prior to closing and will own about 56.5% of the combined entity. Jack Khattar will serve as CEO. Closing is targeted for the fourth quarter of 2026. (Link)
  9. Keensight Capital-backed Isto Biologics has acquired NovaBone Products LLC from Halma plc (LSE: HLMA) for approximately $60 million, expanding its bone graft substitutes platform. Keensight Capital, a pan-European growth buyout manager, has supported portfolio company Isto Biologics in acquiring NovaBone from Halma (LSE: HLMA) for a total consideration of roughly $60 million on a cash-free, debt-free basis. Completed just ten months after Keensight’s investment, this is Isto’s first bolt-on and the opening move in an explicit buy-and-build toward a transatlantic orthobiologics leader. Partners Amit Karna and David Piccoli cited product breadth and geographic reach as the value drivers. Alachua, Florida-based NovaBone sells bioactive glass synthetic grafts in over 40 countries across spine, orthopedic, trauma, extremities and dental applications. (Link)
  10. Eir Partners Capital has made a strategic investment in ClaimsBridge, which simultaneously acquired dialysis cost-containment specialist DialysisPPO, expanding its healthcare cost management ecosystem. Eir Partners Capital, a private equity firm focused on healthcare technology and tech-enabled services, has backed Arnold, Maryland-based ClaimsBridge in a dual transaction announced August 6, 2026. Terms were undisclosed. Founder and CEO Brett Carlson framed the thesis around ClaimsBridge sitting at the point in the claims workflow where pricing and routing decisions are made. The capital funds product development, platform expansion and further M&A. Alongside the investment, ClaimsBridge acquired DialysisPPO, founded 2006, whose patented program has saved payers over $325 million by capturing Medicare savings on dialysis claims without the usual thirty-month coordination period. (Link)
  11. The Difference Card, a Stone Point Capital portfolio company, has acquired healthcare analytics business HealthCorum, expanding its data, provider-scoring and AI navigation capabilities. The Difference Card, the employer health benefits cost-containment platform acquired by Stone Point Capital from Northlane Capital Partners in 2025, has bought HealthCorum. Financial terms were undisclosed. The acquisition adds provider quality scoring across more than 1.5 million providers and over 90 medical subspecialties, folding into the company’s Provider Lookup Manager Tool, plus an AI Navigator supporting natural-language provider search. The strategic logic is margin-relevant: pairing plan-design savings with steerage toward higher-quality, lower-cost providers deepens the value proposition to self-funded employers facing rising trend, and moves the platform from pure cost containment toward navigation. (Link)
  12. Beacon Behavioral Partners, based in Louisiana, has partnered with AR Psychiatric and Counseling Center, marking the physician-led behavioral health expansion into Georgia. Beacon Behavioral Partners, a Baton Rouge-headquartered network of independent interventional psychiatric practices, has entered Georgia through a partnership with AR Psychiatric and Counseling Center. Financial terms were undisclosed and both organisations are private. ARPCC operates two locations serving Valdosta, Tifton and South Georgia under co-lead psychiatrists Anil Gupta, MD, and Bhavesh Patel, MD, who retain the physician-led model. SVP of Business Development Todd Mudd positioned the transaction as preserving clinical autonomy while funding growth. Beacon’s model removes operational burden in exchange for scale, and the platform reported more than 250 providers across 45 locations as of its last disclosed count. (Link)
  13. Bookmark Medical, a provider-led platform has acquired Village Medical Michigan, including Huron Valley Practice Affiliates,  expanding to Michigan and four other states. Bookmark Medical, the Nashville-based primary care platform rebranded from Village Medical earlier in 2026, closed its Michigan entry effective August 3, 2026. Financial terms were undisclosed and both parties are private. The transaction adds seven primary care practices, a diagnostic center and Huron Valley Practice Affiliates, an independent physician organization, comprising roughly 40 providers, over 350 employees and more than 40,000 patients across Southeast Michigan. CEO Benson Sloan and Chief Physician Executive David Hatfield framed the deal around density and provider support. Bookmark now operates across Arizona, Massachusetts, Michigan and Tennessee, with the physician organization adding affiliated-physician reach beyond owned clinics. (Link)
  14. Frazier Healthcare Partners portfolio company LUX Infusion has acquired Infuse IQ, a Cody, Wyoming-headquartered independent infusion therapy provider operating six ambulatory infusion centers. LUX Infusion, the Frazier Healthcare Partners-backed platform formerly known as BioMatrix Specialty Infusion Pharmacy, has added Infuse IQ in its latest tuck-in. Terms were undisclosed. The sponsor’s thesis is site-of-care migration: as payers push infusion out of hospital outpatient departments, LUX is assembling an omnichannel network spanning home infusion and ambulatory centers, now reaching from Alaska to the Southeast. Infuse IQ contributes six clinics serving more than ten specialties with broad payer acceptance and co-pay assistance programs. CEO Brian Zweben cited LUX’s clinician-led model and technology investment as the fit; this follows recent Northeast Infusion Therapy and First Choice deals. (Link)
  15. Versant Diagnostics has acquired American Dermatopathology Laboratory, LLC, a dermatopathology practice based in Centerville, Ohio, and welcomed dermatopathologist H. Nicholas Shamma, MD. Versant Diagnostics, a Grapevine, Texas independent physician services company, has acquired Ohio-based American Dermatopathology Laboratory, extending a national roll-up of subspecialty anatomic pathology practices. Financial terms were not disclosed and both parties are private. The Ohio practice folds into Versant DermPath, the company’s dermatopathology-focused entity, with Dr. Shamma joining as an integral partner. CEO Jim Billington positioned the transaction as building one of the country’s strongest dermatopathologist networks and expanding specialist access. The deal follows Versant’s 2025 expansion into Georgia and reflects a consolidation model that pairs digital pathology infrastructure with physician equity participation. (Link)
  16. Gastro Health has finalized a partnership with Center for Advanced Gastroenterology, a four-physician Central Florida practice. Gastro Health, a national single-specialty digestive and liver health group, has added Center for Advanced Gastroenterology, which operates offices in Maitland and Lake Nona with four board-certified gastroenterologists and two advanced practice providers. Financial terms were undisclosed and both parties are private. CEO Alan Oliver framed the strategy as extending the network by collaborating with high-quality practices in existing markets, and the platform explicitly characterises the transaction as an acquisition milestone in its growth plan. The eighth Orlando-area deal reflects a density-first consolidation approach that concentrates referral flow and ambulatory endoscopy volume within defined geographies. (Link)
  17. Unite Us has acquired Vircho Health, a performance, quality and financial analytics platform for community care networks, strengthening its health and community care infrastructure. Unite Us, the social care coordination network, has acquired Vircho Health including its full team led by co-founders Craig Manson and Evan Jones. Financial terms were undisclosed and both companies are private. The deal responds to a funding shift in social determinants of health, where government payers, health plans and foundations increasingly demand proof of outcomes and quantifiable financial return rather than closed-loop referral confirmation alone. Unite Us brings a thirteen-year dataset of nearly 125 million care connections; Vircho adds dollar-level expenditure tracking and per-organisation performance reporting. Vircho tools already run alongside Unite Us in North Carolina through Impact Health. (Link)
  18. Ascend Learning has acquired Teaching Assignment Management System (TAMS), a cloud-based faculty workload platform built at Duke University. Ascend Learning, a healthcare and learning technology company, has acquired TAMS, used by more than 70 institutions including Johns Hopkins, Texas A&M and Marquette. Terms were undisclosed. CEO Lissy Hu framed the rationale as owning the full continuum from faculty planning through student outcomes, building on ATI Nursing Education’s penetration of more than 60% of U.S. nursing schools. The strategic value is cross-sell into an installed base at a moment when nursing programs face faculty shortages and enrolment pressure. Founder David Parrish cited Ascend’s distribution reach as the deal driver; the platform replaces spreadsheet-based assignment and workload processes. (Link)
  19. Copley Equity Partners portfolio company FMG Leading has acquired Washington, D.C.-based market intelligence and strategic advisory firm BroadBranch Advisors, adding competitive and customer intelligence capabilities to its healthcare advisory platform. FMG Leading, a Philadelphia-based strategic advisory firm founded in 1984 and backed by Copley Equity Partners since 2022, closed its purchase of BroadBranch Advisors effective July 31, 2026. Terms were undisclosed and both firms are privately held. The sponsor thesis is capability stacking rather than scale: FMG advises investor-backed healthcare executives on growth and value creation, and BroadBranch contributes an “outside-in” competitive and customer intelligence practice, combining market insights with organisational health data on one platform. CEO and Chairman Matt Brubaker cited rising client demand for faster translation of forward-looking intelligence into action. BroadBranch Managing Partner Courtney Matson continues with the combined business. (Link)
  20. Tortuga Growth Partners has made a strategic investment in Advanced eClinical Training, an online healthcare certification and workforce development provider, through Tortuga Growth Partners Fund I, L.P. Tortuga Growth Partners, a New York private investment firm built around disciplined buy-and-build, has invested in Advanced eClinical Training out of its debut fund, extending the build-out of its healthcare vertical. Terms were undisclosed. Managing Member Ashray Prasad framed the thesis as backing founders addressing large, enduring problems with structural tailwinds, citing an American Hospital Association projection of a 3.2 million-worker healthcare shortage this year. Senior Managing Director Walt Vester will help scale the platform. Tortuga has assembled a board and advisory group including operating partners Michael O’Neil, who becomes executive chair, Vester and Marty DeMonte alongside co-founders Shay and Shabnam Safarzadeh. (Link)
  21. GreyLion and Vestar Capital Partners portfolio company 360training.com, Inc. has acquired select assets of seven San Antonio-based compliance training brands, including American Health Training and National OSHA Foundation. 360training, an Austin-based regulated online training platform owned by GreyLion and Vestar Capital Partners, has executed another add-on in a rapid buy-and-build cadence that already includes ACLS Medical Training, Canadian Food Safety Group and the On The Fly brands in 2026 alone. Terms were undisclosed. The acquired portfolio spans healthcare, OSHA and workplace safety, food handling, forklift operations, hazardous materials, defensive driving and transportation safety, broadening the sponsors’ multi-industry compliance footprint across the United States and Canada. The strategy is consolidation of fragmented, mandatory-certification niches where regulatory complexity supports recurring, non-discretionary demand. (Link)
  22. Lee Health has acquired Gardner Orthopedics, a Fort Myers orthopedic practice, expanding the nonprofit system’s musculoskeletal service line across Southwest Florida. Lee Health, a Southwest Florida nonprofit health system, has acquired Gardner Orthopedics, absorbing all 75 employees including five physicians alongside nurses, physical therapists and medical assistants. Financial terms were not disclosed; as a nonprofit system acquisition of a physician practice, no sponsor capital is involved. Kris Fay, Chief Administrative Officer of LPG and Ambulatory Care, positioned the deal as expanding access to orthopedic and musculoskeletal care. The Winkler Avenue facility remains operational, strengthening outpatient footprint. The transaction supports the Lee Health Musculoskeletal Institute build-out at a time of sustained population growth in the region. (Link)
  23. Philips International has completed the acquisition of the healthcare consulting, technology and recruiting businesses of The Nash Group, Inc., Advance Solutions International, Inc. and Nursing Advisory Services LLC. Philips International, a Great Neck, New York privately held investment company has closed its purchase of the Nash healthcare businesses. Financial terms were undisclosed. Adrian Miller, Managing Director of Corporate M&A at Philips International, cited the platform’s expertise, longstanding customer relationships and differentiated workforce solutions, and said the buyer will invest in people, technology, business development capability and operating infrastructure. Established in 1992, The Nash Group serves hospitals across staffing optimisation, acuity and workload analysis, operational performance improvement, hospital technology, and domestic and international nurse recruitment. (Link)
  24. Codis completes acquisition of Catalent’s Nottingham, UK facility Codis, a global CDMO specializing in spray drying and amorphous solid dispersions, has closed its acquisition of Catalent’s Nottingham, UK facility. The site adds oral solid dose development, clinical supply and small-scale commercial manufacturing capabilities, complementing Codis’ commercial-scale spray drying operations in Haverhill. The combination creates an integrated European pathway from early development through commercial intermediates and finished dose forms. Financial terms were not disclosed. (Link)
  25. Nexa Equity portfolio company Facility Grid has acquired PingCx, an autonomous commissioning platform for building automation systems, and launched a unified building lifecycle software platform. Facility Grid, a Waltham, Massachusetts commissioning and operational readiness software provider backed by San Francisco-based growth equity firm Nexa Equity, has acquired PingCx. Terms were undisclosed. Nexa manages more than $1 billion in assets and runs a concentrated investment approach pairing investors with operators. The acquisition converts Facility Grid from a point commissioning tool into a three-product platform, with PingCx becoming FG Validate alongside FG Construct and FG Sustain, the latter launching in September. CEO Daniel Russo positioned the strategy around owning the system of record across a building’s full life rather than only its construction phase. (Link)
  26. Sheridan Capital Partners has completed its investment in Carolina Components Group, a Durham, North Carolina supplier of custom-engineered bioprocessing assemblies to biopharmaceutical manufacturers. Sheridan Capital Partners, a healthcare-dedicated private equity firm investing $30 million to $150 million per manufacturing deal out of its $575 million Fund III, has closed a private investment in Carolina Components Group. Financial terms were undisclosed. Partner Michael Bernard described CCG as the output of a multi-year thesis in the pharmaceutical manufacturing supply chain, with the deal led alongside Sean Dempsey and Conor Kolstad. Founder John Cooling and other leaders retain meaningful ownership and Cooling joins the board, while Maurice Phelan, formerly President of Sartorius North America, becomes CEO. CCG serves over 250 biopharma and CDMO customers. (Link)
  27. Neuronetics, Inc. (NASD: STIM) and second-largest shareholder Jorey Chernett of Pointillist Family Office have reached an agreement establishing a path to board representation, with largest holder Madryn Asset Management, LP reaffirming its support. Neuronetics (NASDAQ: STIM) has resolved a months-long campaign by Jorey Chernett, whose Pointillist Family Office holds 14.12% of shares outstanding and 10,588,988 shares with sole voting and dispositive power. Chernett had criticised chronic underperformance since the $45 million Greenbrook TMS acquisition in late 2024 and pushed for a sale of the TMS device business; the company is not pursuing that route. Under the understanding, Chernett may recommend a new board appointee and has affirmed comfort with the capital position. Madryn Asset Management Managing Partner Avi Amin, also a director, reaffirmed conviction in the platform. (Link)
  28. iSpecimen Inc. (NASD: ISPC) has closed a $5.0 million public offering of common stock and pre-funded warrants, with participating investors subscribing for 996,231 shares and warrants over up to 2,849,923 additional shares. iSpecimen (NASDAQ: ISPC), an online marketplace connecting biospecimen researchers with healthcare specimen providers, priced the offering on August 6 and closed August 7, 2026 for gross proceeds of approximately $5 million. The heavy pre-funded warrant component relative to common stock indicates investors managing beneficial ownership thresholds, a common structure for micro-cap issuers with concentrated demand. Proceeds are earmarked for repayment of outstanding liabilities, potential acquisitions and investments, marketing initiatives, general corporate purposes and working capital. The registration statement was filed June 24, 2026 and declared effective July 30, 2026. (Link)
  29. Health Catalyst, Inc. (NASD: HCAT) has completed the sale of its Vitalware mid-revenue-cycle business to Med-Metrix LLC for $147 million in cash and used the proceeds to fully retire its credit facility. Health Catalyst (NASDAQ: HCAT) closed the divestiture of Vitalware to Med-Metrix on July 31, 2026 for $147 million of total cash consideration, subject to customary adjustments. Proceeds plus balance-sheet cash repaid and terminated all obligations under the company’s credit facility, eliminating roughly $19 million of annualised GAAP interest expense based on first-half 2026 figures. The transaction is a balance-sheet reset as much as a portfolio move: management framed the strengthened capital position as funding a narrower roadmap around cost management, clinical quality and consumer loyalty intelligence products. Med-Metrix gains coding compliance, chargemaster, charge capture and price transparency assets. (Link)
  30. Solventum Corporation (NYSE: SOLV) has reported second quarter 2026 results and announced plans to separate its Health Information Systems division, following the earlier divestiture of its Purification and Filtration business. Solventum (NYSE: SOLV) posted $2.2 billion of second quarter sales with 9.5% organic growth against 2.2% reported growth, and raised full-year guidance. The capital-structure story is the more investor-relevant one: net debt has fallen $2.6 billion since separation from 3M (NYSE: MMM) to $4.7 billion, funded largely by net proceeds from the September 2025 sale of Purification and Filtration. Management then announced its intention to spin off Health Information Systems, a second act of portfolio separation for a company itself created by spin-off. Shares rose 3.4% after hours to $90.47, surpassing the prior 52-week high. (Link)
  31. Care Options for Kids has completed the rebranding of its Chicago-area affiliate Health Force under the Care Options for Kids name, unifying its Illinois pediatric home care identity. Care Options for Kids, a national pediatric home healthcare provider, announced that Health Force has formally transitioned to the Care Options for Kids brand, establishing a single identity in Illinois. No new transaction, consideration or investor was disclosed: Health Force was already part of the platform, making this an integration and branding milestone rather than a fresh acquisition. Operating in the Chicago area since 1993, the business continues providing one-to-one pediatric care at home, in schools and in communities, with local clinicians gaining access to the platform’s shared clinical resources and standardised processes. (Link)

Venture Deals and Other

  1. Standard Capital has led a $15 million Series A in San Francisco-based Andromeda Surgical, with participation from Y Combinator, Vox Capital, Lingotto Innovation, Alumni Ventures, WestWave Capital, Pioneer Fund and Phaze Ventures. Standard Capital led the $15 million round for Andromeda Surgical, taking total funding to $30 million as the autonomous surgery company moves from clinical validation to commercial launch. Pioneer Fund has now backed the company twice, starting at seed, and Oman-based Phaze Ventures participates from its earlier investment. Investors are underwriting an endourology-first thesis: the system has performed HoLEP procedures in more than 40 patients across three countries, with enucleation times as fast as 30 minutes against a published average near 90. Andromeda holds clearance in Canada and New Zealand, with first commercial installations expected within two months. (Link)
  2. Strategic investors NDS Corporation and Aimed Bio Inc. have backed Inocras Inc.’s oversubscribed $31 million Series B-3 alongside new investors IMM Investment, Korea Investment & Securities, LoftyRock Investment, DT& Investment, Woori Investment & Securities and Shinhan Securities, with existing holders DSC Investment, Dunamu & Partners and InterVest participating. The oversubscribed Series B-3 takes San Diego-based Inocras to approximately $100 million of total funding. The investor syndicate is notably Korea-weighted, reflecting the company’s origins as a KAIST spinout and its installed base across Asia. Capital funds U.S. commercial and operational build-out of its CLIA/CAP-certified whole-genome sequencing and automated bioinformatics infrastructure. Investors are backing demonstrated traction rather than early-stage risk: the platform is used by more than 100 cancer institutions, supports roughly 30 South Korean hospitals and holds meaningful commercial presence in Hong Kong. Strategic participation from Aimed Bio follows a July equity investment and joint research agreement. (Link)
  3. UMass Memorial Health has led the $10 million first close of Wellinks’ Series B round, with participation from existing inside investors. UMass Memorial Health, a strategic rather than financial investor, anchored the $10 million first tranche for New Haven-based Wellinks, deepening a multiyear commercial relationship that began with a 2022 UMass Chan research collaboration and a 2024 virtual pulmonary rehabilitation partnership. The investment is underwritten by outcomes data: the joint Healthy at Home study showed participants with more than 60% lower odds of 30-day COPD readmission. Proceeds fund commercial expansion into rural and underserved markets, advance the predictive analytics engine behind the FDA-cleared Spire remote monitoring system, and extend the care model into congestive heart failure. Inside investors supported the round. (Link)
  4. Boost VC, Cleo Capital, Manna Ventures and Profluent Capital have backed SkinBit’s $6 million pre-seed round, joined by Lyft, Inc. (NASD: LYFT) co-founder Logan Green and nine board-certified dermatologists. The $6 million pre-seed for Los Angeles-based SkinBit is an unusually well-syndicated first institutional round, pairing four venture funds with an operator angel in Lyft (NASDAQ: LYFT) co-founder Logan Green, who joins the board, and nine practising dermatologists whose participation doubles as clinical distribution. Investors are funding a data-asset thesis rather than a device: proceeds deploy full-body scanners into med spas, longevity clinics and dermatology practices, targeting three locations in 2026 and fifteen by end-2027, with each scan compounding a longitudinal, patient-owned imaging record. Founded 2023 by Jonathan Benassaya, with Stanford and OHSU dermatology leadership attached. (Link)
  5. 4DMedical Limited (ASX: 4DX) has made a $3.4 million strategic investment in Seattle-based RevealDx and signed a global distribution agreement for the RevealAI-Lung nodule characterisation software. 4DMedical (ASX: 4DX) is combining a $3.4 million equity investment with exclusive distribution rights across the United States, Europe, Australia and New Zealand, a structure that gives the listed acquirer optionality on RevealDx without full consolidation. The investment follows 4DMedical’s acquisition of Austrian chest CT company contextflow, into whose platform RevealAI-Lung is already integrated and deployed at European clinical sites. The commercial case rests on reimbursement and regulatory position: FDA clearance, European MDR certification, Australian TGA approval and U.S. Medicare coverage under CPT codes 0721T and 0722T, with validation across more than 1,500 patients. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update July 27th, 2026

LECO_Weekly-Healthcare-News_7-27-2026Download
  1. Longshore Capital Partners entered a strategic growth partnership with revenue cycle management provider Prochant. Chicago-based Longshore Capital Partners, a lower middle-market private equity firm that takes control positions in North American services businesses with $5 million to $15 million of EBITDA, invested in Prochant, a Charlotte, North Carolina technology-enabled RCM provider serving home medical equipment, DME, infusion and specialty pharmacy operators. Terms were undisclosed. Capital will fund technology, analytics, AI and automation investment, service capacity expansion, new revenue cycle product development and talent acquisition, alongside acquisitions in core markets. Longshore is backing an existing management team under CEO Joey Graham, preserving leadership and culture while accelerating investment in a recurring-revenue outsourced services model. (Link)
  2. SkyKnight Capital, L.P. agreed to acquire a controlling position in Apex Infusion from FFL Partners, which retains a minority stake alongside the clinician-led management team. SkyKnight Capital, a San Francisco private equity firm, signed a definitive agreement to partner with Apex Infusion, a Signal Hill, California omnichannel infusion services provider founded in 2006. FFL Partners, which completed its investment in 2024, remains a minority shareholder, and Apex’s clinician-led management retains significant ownership and continues to lead the business. Apex delivers therapy through a home infusion nursing network and roughly 40 ambulatory infusion suites. SkyKnight intends to fund new market entry, health system and payor partnerships, and technology-enabled access initiatives across a site-of-care shift thesis. (Link)
  3. Winterbird Partners made a growth investment in Minneapolis-based Microsoft services partner Emergent Software. Winterbird Partners invested in Emergent Software, a Minneapolis, Minnesota Microsoft services partner specializing in data modernization, AI deployment, cloud transformation, application development and managed services. Deal value was not disclosed. Led by CEO Jamie Anderson, Emergent manages solutions across the Microsoft ecosystem including Fabric, Azure, Copilot, Foundry and modern data platforms. Proceeds will fund headcount expansion, additional service capabilities and entry into new geographies. For Winterbird, the transaction is a bet on the durability of enterprise AI and data-platform implementation, backing a founder-led services firm against a single hyperscaler ecosystem rather than horizontal consultancy model. (Link)
  4. Healthcare technology platform Focus entered a definitive agreement to acquire Plano, Texas-based managed technology services company GuideIT. Focus, a Chicago-headquartered healthcare technology services company, agreed to acquire GuideIT, a nationally recognized managed technology services provider offering managed IT, cybersecurity, cloud integration, IT and clinical service desk, and medical data services. Terms were undisclosed; GuideIT will operate as GuideIT, A Focus Company. Focus supports more than 100 electronic health record and practice management systems and is consolidating fragmented healthcare vendor relationships into a single accountable partner. GuideIT CEO and board member Russell Freeman described a deliberate partner selection process. The acquisition scales Focus’s Unified Healthcare Platform thesis through capability breadth rather than geographic density. (Link)
  5. Knox Lane completed its $437 million take-private acquisition of Cross Country Healthcare, Inc. (formerly NASD: CCRN), concurrently selling the locums division to portfolio company All Star Healthcare Solutions. Growth-oriented investment firm Knox Lane closed its all-cash acquisition of Cross Country Healthcare at $13.25 per share, valuing the technology-enabled workforce solutions company at roughly $437 million and ending its NASD listing. The deal follows a terminated agreement with Aya Healthcare. Knox Lane simultaneously moved Cross Country’s locum tenens division into All Star Healthcare Solutions, an existing portfolio company, creating immediate platform consolidation. Managing Partner John Bailey and Partner Shamik Patel cited the company’s position at the intersection of workforce services and technology. Joel Tremblay, formerly of Medical Solutions, was installed as CEO, succeeding co-founder Kevin Clark. (Link)
  6. Care Career acquired MAS Medical Staffing, completing its first acquisition phase and lifting consolidated annual revenue beyond $150 million. Woodbridge, New Jersey-based Care Career, a healthcare workforce technology organization led by CEO Siva Konatham, acquired Manchester, New Hampshire-based MAS Medical Staffing, including its travel, allied and per diem operations and technology assets. Financial terms were undisclosed. This is Care Career’s seventh acquisition in 24 months, following IDR Healthcare in February 2026, Source Medical Staffing in October 2025, and four firms in May 2025. The completed first round now exceeds $150 million of annual revenue, with signed LOIs expected to close in Q3 2026 pushing consolidated revenue past a quarter billion by year-end, aided by MAS’s Maestra workforce platform. (Link)
  7. Equality Asset Management-backed Mindoula acquired Valera Health and Janus Healthcare Partners in a double transaction expanding its whole-person care enablement platform. Mindoula, the Silver Spring, Maryland behavioral health company backed by Equality Asset Management, simultaneously acquired New York-based virtual mental health provider Valera Health and Duxbury, Massachusetts psychiatric collaborative care provider Janus Healthcare Partners. Terms were undisclosed. These are Mindoula’s third and fourth acquisitions since its 2013 founding, following Care at Hand and 180 Health Partners. Valera contributes more than 300 multi-state behavioral providers and specialization in suicide risk reduction, DBT and serious mental illness; Valera had itself raised $74.3 million and acquired Vita Health in 2025. Janus adds psychiatry CoCM capability, positioning Mindoula for value-based contracts with payers and health systems. (Link)
  8. Beacon Behavioral Partners entered Ohio and Michigan through a partnership with Ohio- and Michigan-based Pure Psychiatry, adding a 17-location outpatient platform. Plano, Texas-based Beacon Behavioral Partners, a growing network of independent psychiatric practices, acquired Pure Psychiatry, establishing its first presence in Ohio and Michigan and marking one of its largest expansions to date. Financial terms were undisclosed. Pure Psychiatry, led by founders Taylor Hennrick, PA-C, Sarang Patel, PA-C and Dr. Rakesh Amin, provides psychiatric care across all age groups including medication management for anxiety, depression, ADHD and bipolar disorder. Beacon will supply operational, administrative and strategic support to fund de novo clinic openings and provider recruitment. The deal follows Beacon’s appointment of Rob Jardeleza as CEO roughly a week earlier. (Link)
  9. Truehelm-backed Wildflower Health acquired digital pelvic floor platform Every Mother, marking its entry into direct-to-consumer women’s health. Wildflower Health, the San Francisco tech-enabled women’s health company backed by Truehelm, acquired Every Mother, a clinically validated core and pelvic floor therapy platform founded by Allison Rapaport. Terms were undisclosed. Wildflower operates enterprise infrastructure connecting commercial health plans, risk-bearing provider groups and patients across all 50 states, supporting thousands of women’s health providers. Every Mother contributes HSA/FSA-eligible on-demand exercise programs addressing diastasis recti, urinary incontinence, pelvic organ prolapse and pelvic pain. Strategically, the acquisition adds a consumer subscription revenue channel to an enterprise contracting model and extends patient relationships beyond the traditional six-to-twelve-week postpartum drop-off. (Link)
  10. DuneGlass Capital-backed Aviva Aesthetics expanded into Ohio through a partnership with Avon, Ohio-based Vitality Health. Aviva Aesthetics, the Chicago-based entrepreneur-owned medical aesthetics platform launched in 2024 with healthcare services independent sponsor DuneGlass Capital, partnered with Vitality Health, a medical aesthetics and wellness practice in Avon, Ohio founded in 2014 by Alana Mercer, PA-C. Terms were undisclosed. This is Aviva’s eighth partnership of 2026 and its first Ohio location, deepening Midwest presence. Vitality Health provides injectables, laser treatments, skin rejuvenation, weight management and hormone optimization. Aviva’s Entrepreneur Equity structure explicitly positions against traditional private equity roll-ups, allowing founders to retain full equity and control while accessing scale economics and back-office support. (Link)
  11. PE-backed Premier Care Dental Management acquired cosmetic dentistry practice Brookline Smile Artists in Massachusetts. Premier Care Dental Management, the New Hyde Park, New York dental clinical organization operating under the Dental365 brand and backed by The Jordan Company, added Brookline, Massachusetts-based Brookline Smile Artists to its network. Terms were undisclosed. PCDM supports practices across New York, Connecticut, New Jersey, Pennsylvania, Ohio, New Hampshire, Massachusetts and Rhode Island, and has pursued an acquisition-led growth cadence including multiple Ohio additions earlier in 2026. The tuck-in extends the sponsor-backed platform further into higher-margin cosmetic dentistry, a service line with meaningful cash-pay mix, while continuing the roll-up strategy aimed at retiring and scaling-back owner-dentists across the Northeast. (Link)
  12. Shore Capital Partners-backed Innovate 32 partnered with Houston-based Post Oak Dental, expanding its Texas dental support organization footprint. Innovate 32, the Nashville-based dental services organization formed by Chicago lower middle-market private equity firm Shore Capital Partners, closed a partnership with Post Oak Dental, an established Houston, Texas practice. Terms were undisclosed. Under CEO Josh Johnson and a board combining dentists, multi-site healthcare operators and private equity executives, Innovate 32 has assembled a network across Texas, Tennessee, Florida and the Mid-Atlantic since its 2024 founding. Post Oak Dental retains its clinical focus while gaining management infrastructure. For Shore, the affiliation continues a disciplined buy-and-build in general dentistry, prioritizing clinician alignment and local leadership over transactional roll-up. (Link)
  13. Dentalcorp entered the U.S. market with the acquisition of Florida-based Northstar Dental Partners. Toronto-based Dentalcorp, one of the largest dental support organizations in North America, acquired Northstar Dental Partners, a Boca Raton-headquartered group supporting 21 dental practices across South Florida, the Treasure Coast, Southwest Florida and Central Florida. Founder and CEO Dr. Jordan Tomalty retains an ownership stake and will remain instrumental to continued growth. Combined with Dentalcorp’s Canadian network, the partnership brings the total to over 650 supported practices. (Link)
  14. vybe urgent care acquired Liberty Urgent Care’s Horsham and Hatfield centers, supported by growth-oriented debt financing from Live Oak Bank. vybe urgent care, the leading independent urgent care operator in greater Philadelphia, acquired Liberty Urgent Care’s two Montgomery County, Pennsylvania centers, expanding its network from 16 to 18 sites. Terms were undisclosed. The transaction was funded through a recent growth-oriented refinancing completed with Live Oak Bank, which vybe intends to draw on for further acquisitions and de novo development. Liberty founder Erik Soiferman, D.O. joins as Vice President of Occupational Medicine Services, strengthening vybe’s occupational health and workers’ compensation capabilities. The debt-funded structure allows the independent operator to consolidate a fragmented regional market without an equity sponsor. (Link)
  15. Ares Management Corporation (NYSE: ARES) and Rubicon Founders-backed US Heart & Vascular acquired Tennessee physician-owned practice Apex Vascular and its outpatient center. US Heart & Vascular, the Nashville-area cardiovascular support services platform backed by funds managed by the Private Equity Group of Ares Management (NYSE: ARES) alongside Rubicon Founders, acquired Apex Vascular and Apex Vascular Outpatient Center. Terms were undisclosed. Headquartered in Lenoir City, Tennessee, Apex has served East Tennessee for nearly two decades across Knoxville, Crossville, Harrogate, Decatur, Sevierville and Oak Ridge, treating peripheral artery disease, varicose veins, carotid artery disease and dialysis access. Founder Christopher Pollock, MD cited access to resources for regional expansion. The tuck-in deepens USHV’s density in a specialty prized for recurring outpatient procedure volume. (Link)
  16. Paradigm Oral Health bought back BlackRock, Inc.’s (NYSE: BLK) Long Term Private Capital stake in a surgeon-led transaction backed by a Warburg Pincus-led group including Goldman Sachs (NYSE: GS) Alternatives and Sixth Street. Lincoln, Nebraska-based Paradigm Oral Health repurchased BlackRock Long Term Private Capital’s ownership stake, returning majority control to its surgeons and management. The buyback is funded by a significant investment led by Warburg Pincus, a private partnership since 1966, in partnership with Goldman Sachs (NYSE: GS) Alternatives and Sixth Street. Terms were undisclosed. Founded in 2018 by David Rallis, DDS, MD, Paradigm operates an oral surgery and digital dentistry platform built to attract and retain surgeons. The structure is notable for reversing conventional sponsor control: incoming capital supports clinician majority ownership, technology investment, advanced training and de novo clinic expansion. (Link)
  17. Groups Recover Together acquired Better Life Partners in its first-ever acquisition, doubling its New England patient volume.Burlington, Massachusetts-based Groups Recover Together, the value-based opioid use disorder treatment provider backed by Oak HC/FT, Bessemer Venture Partners, Transformation Capital, RRE Ventures, Optum Ventures and Kaiser Permanente Ventures, acquired Better Life Partners in a transaction that closed March 31. Financial terms were undisclosed. Better Life Partners, founded in Vermont in 2018 and backed by aMoon, Alumni Ventures, F-Prime Capital, Maverick Ventures and .406 Ventures, had raised $26.5 million in a 2023 Series B but experienced financial distress. CEO Cooper Zelnick highlighted mental health and virtual primary care capabilities the company intends to scale nationally beyond New England. (Link)
  18. Ohio-based Cardinal Health (NYSE: CAH) agreed to acquire the Diabetes Health business of AdaptHealth Corp. (NASD: AHCO) and, in its entirety, NMS Capital-backed Strive Medical for approximately $360 million in cash. Cardinal Health (NYSE: CAH), headquartered in Dublin, Ohio, deployed roughly $360 million of cash across two definitive agreements to scale its at-Home Solutions platform, subject to working capital adjustments. The AdaptHealth (NASD: AHCO) unit serves over 225,000 patients annually through a centralized mail-order CGM model, while NMS Capital portfolio company Strive Medical adds urology, wound care, ostomy and incontinence supply distribution to 20,000-plus patients. Both transactions build on Cardinal’s Advanced lDiabetes Supply acquisition and are expected to be accretive to non-GAAP EPS within twelve months of close, extending the Ohio distributor’s consolidation of fragmented direct-to-patient supply channels. (Link)
  19. Surgery Partners, Inc. (NASD: SGRY) agreed to sell its ownership interests in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health for approximately $795 million. Surgery Partners (NASD: SGRY), the Brentwood, Tennessee short-stay surgical facility operator, placed into escrow signature pages to sell its Idaho Falls hospital interests to existing partner Intermountain Health, a Utah-based nonprofit system of 34 hospitals and roughly 400 clinics. The transaction values the combined facilities at approximately $1.15 billion, with total consideration to Surgery Partners of about $795 million before purchase price adjustments. Physician ownership of Mountain View Hospital is unchanged. CEO Eric Evans framed the divestiture as portfolio optimization, refocusing capital toward ambulatory surgery centers. The company reaffirmed 2026 revenue guidance of $3.35–$3.45 billion excluding transaction impact. (Link)
  20. Gentherm Incorporated (NASD: THRM) acquired Ohio-based Innovative Medical Equipment, LLC, maker of the ThermaZone thermal therapy device. Gentherm (NASD: THRM), the Novi, Michigan thermal management and pneumatic comfort technology leader, acquired Innovative Medical Equipment, a Cleveland-area, Ohio provider of the ThermaZone non-opioid hot-and-cold thermal therapy system. Terms were undisclosed. Founder and President Brad Pulver framed Gentherm’s scale and global operating footprint as the growth enabler for the Ohio business. Management expects revenue synergies from cross-selling ThermaZone through Gentherm’s expanded healthcare customer channels. Announced alongside record Q2 2026 revenue of $416 million, raised full-year guidance and a new $400 million repurchase authorization, the deal advances Gentherm’s strategic pivot toward higher-margin medical adjacencies. (Link)
  21. RS2 Healthcare Partners, the Boston-based private equity firm formerly known as Riverside Partners, completed an investment in KMM Group, a Hatboro, Pennsylvania-based vertically integrated precision contract manufacturer serving the medical device industry. RS2 Healthcare Partners, founded in 1989 and rebranded from Riverside Partners in May 2026 to formalize an exclusive lower-middle-market healthcare strategy, closed an investment in KMM Group. Terms and stake size were undisclosed. The firm has raised $1.6 billion in total capital commitments since inception and concentrates on pharma services, medical device contract manufacturing and technology-enabled healthcare, supported by healthcare, clinical and AI advisory boards. KMM produces complex, tight-tolerance components for failure-intolerant end markets. J. Mark King joins as President and CEO, while co-founders John Shegda and Eric Wilhelm move to Chief Technology Officer and Executive Vice President, Business Transformation, preserving customer and employee continuity under sponsor ownership. (Link)
  22. Eurofins Scientific (EUFI.PA) agreed to acquire Element Materials Technology’s Life Sciences Testing Services business in North America for an enterprise value of $400 million. Eurofins Scientific, a global leader in bioanalytical testing, reached agreement with Element Materials Technology to acquire its North America Life Sciences Testing Services business, encompassing biopharma product testing, environmental testing and food testing across a network of 27 laboratories and facilities employing approximately 750 FTEs. The business is expected to generate over $150 million in 2026 revenues with profitability in line with the Eurofins Group average. The transaction expands Eurofins’ geographic footprint in key U.S. and Canadian regions where it has been underrepresented and is expected to close in Q4 2026 subject to customary regulatory approvals. (Link)
  23. Repligen Corporation (NASD: RGEN) agreed to acquire BioLife Solutions, Inc. (NASD: BLFS) for a total enterprise value of approximately $1.5 billion. Repligen will acquire BioLife in a cash-and-stock transaction valued at $31.00 per BioLife share ($11.25 cash plus 0.1442 shares of Repligen common stock), representing a 24% premium to the 90-day VWAP. The deal adds BioLife’s market-leading biopreservation media platform (including CryoStor) and cell-processing tools that support 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based trials. The transaction is expected to be accretive to growth, margins and adjusted EPS (at least 5 cents in year one and 25 cents in year two) with $20–30 million of synergies; closing is targeted for Q4 2026. (Link)
  24. Nordic Capital agreed to sell life sciences software platform ArisGlobal to Dassault Systèmes (Euronext Paris: DSY) for up to $2 billion, marking a full exit for the Swedish sponsor. Nordic Capital, which manages approximately €39 billion, is exiting ArisGlobal entirely in a sale to Dassault Systèmes (Euronext Paris: DSY) reported at $1.8 billion cash plus a $200 million earnout. Nordic first invested in 2019 via its ninth fund at a reported $700 million enterprise value and added to its stake in 2021. Under Nordic’s ownership the Waltham, Massachusetts company converted to SaaS, completed two bolt-ons and is expected to generate roughly $175 million of 2026 revenue, processing 12 million safety cases annually for 200-plus customers. Closing is expected in the second half of 2026. (Link)
  25. Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) entered a definitive agreement to acquire certain cannabis cultivation, manufacturing and retail assets of The Cannabist Company Holdings Inc. across five markets for up to $35 million. Vireo Growth, through subsidiary Vireo Health of Arcadia, agreed to acquire selected operations from Cannabist subsidiaries in Colorado, Illinois, Massachusetts, New Jersey and West Virginia for total consideration of up to US$35 million (up to US$18.75 million cash at closing plus up to US$16.25 million in seller notes), subject to adjustments and regulatory approvals. The staged transaction is expected to add up to 25 dispensaries plus cultivation and production assets, deepening Vireo’s Colorado presence and adding four new states. Closing is targeted through 2026 into 2027 amid Cannabist’s CCAA and Chapter 15 proceedings. (Link)
  26. Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) agreed to acquire Planet 13 Holdings Inc. (CSE: PLTH; OTCQX: PLNH) in an all-share merger. Vireo Growth entered a definitive merger agreement to acquire all outstanding equity of Planet 13, with each Planet 13 share converting into 0.015383618 of a Vireo subordinate voting share (16.6% premium to the 20-day VWAP and 24% premium to the closing price as of July 24, 2026). The transaction deepens Vireo’s Nevada and Florida footprints (adding the flagship Las Vegas superstore, additional dispensaries, cultivation/production capacity and licenses) and adds a Waukegan, Illinois dispensary. On a pro forma basis with prior announced deals, Vireo expects to operate approximately 265 dispensaries across 15 states. Closing is subject to stockholder, regulatory and listing approvals. (Link)
  27. First Choice Healthcare Solutions, Inc. (OTCQB: FCHS) and Westin Acquisition Corp. (NASD: WSTN) announced a definitive business combination agreement to create a publicly traded healthcare and wellness company. The transaction values First Choice at a pro forma enterprise value of approximately $650 million and is expected to accelerate its strategic rebrand to Wellgevity 360, a platform focused on longevity, preventative care and personalized biology-driven solutions. Westin will domesticate and the combined company is expected to trade on NASD. Closing is targeted for Q4 2026 subject to customary approvals and conditions. (Link)
  28. Avanos Medical, Inc. (NYSE: AVNS) stockholders approved the company’s $25.00-per-share take-private by American Industrial Partners, valuing the medtech at roughly $1.272 billion. Avanos Medical (NYSE: AVNS) shareholders voted overwhelmingly in favor of the acquisition by affiliates of funds advised by American Industrial Partners, with approximately 99.75% of shares voted supporting the merger, representing about 74.96% of shares outstanding as of the June 18 record date. Holders receive $25.00 per share in cash, an enterprise value near $1.272 billion and a 72.1% premium to the pre-announcement close, plus an 82.8% premium to the 30-day VWAP. All regulatory approvals had been obtained, with closing expected no later than July 27, 2026. The operationally focused industrials investor takes Avanos private, delisting from the NYSE. (Link)
  29. Royalty Pharma plc (NASD: RPRX) acquired a portion of Neurimmune’s royalty interest in cliramitug for up to $425 million. Royalty Pharma (NASD: RPRX) committed up to $425 million to Zurich-based Neurimmune in exchange for a 3% to 4% royalty on worldwide net sales of cliramitug, an investigational anti-amyloid antibody for ATTR cardiomyopathy. The structure front-loads $125 million upfront, with a further $125 million payable in Q1 2027 and $175 million tied to clinical and regulatory milestones. Cliramitug is licensed globally to Alexion, AstraZeneca Rare Disease, which is running the Phase 3 DepleTTR-CM trial. For Royalty Pharma, the transaction buys exposure to the rapidly growing ATTR-CM market; for Neurimmune, it is non-dilutive capital funding its internal pipeline. (Link)
  30. Aurobindo Pharma Limited (NSE: AUROPHARMA; BSE: 524804), through wholly owned subsidiary Apitoria Pharma Private Limited, agreed to acquire 80% ownership control of A1 Biochem Labs (India) Private Limited and A1 Biochem Labs LLC, USA at a $17 million enterprise value. Aurobindo Pharma (NSE: AUROPHARMA; BSE: 524804) is deploying $13.6 million in cash through Apitoria Pharma for an 80% interest in A1 Biochem Group’s contract research business, struck at a $17 million enterprise value on a debt-free, cash-free basis, subject to closing adjustments. The existing promoter retains 20%, and A1 Biochem Labs (India) will absorb A1 Biochem Labs LLC and the CRO business of A1 Biochem Research (India). The target posted FY26 turnover of ₹1,024.42 million and EBITDA of ₹465.46 million — a 45% margin — across Wilmington and Hyderabad labs with 90-plus scientists. Aurobindo is building an integrated CRDMO platform across the API value chain; closing is expected in 90 to 120 days. (Link)
  31. Scancell Holdings plc (AIM: SCLP) and Neuphoria Therapeutics Inc. (NASD: NEUP) announced an all-share merger agreement and associated financing. Scancell will acquire Neuphoria in an all-share transaction; the combined company will operate as Scancell, list on NASD (in addition to AIM) and advance a pipeline of targeted, off-the-shelf active immunotherapies, led by iSCIB1+ in advanced melanoma. Existing Scancell shareholders are expected to own approximately 85.5% and Neuphoria shareholders 14.5% on a pro forma basis (before financing). Concurrent financing of up to $89 million (equity and debt) is intended to fund the global registrational Phase 3 trial. Closing is targeted for late Q4 2026 subject to shareholder and regulatory approvals. (Link)
  32. Footbridge Partners and ALZA Capital Partners sold Ohio-, Pennsylvania- and Michigan-based medical spa platform The Skin Center to an undisclosed middle-market healthcare private equity fund. Footbridge Partners and ALZA Capital Partners exited The Skin Center, a medical spa and cosmetic surgery platform operating 14 locations across Pennsylvania, Ohio and Michigan, selling to an unnamed middle-market healthcare private equity fund in a recapitalization. Terms were undisclosed. Founded in 1981 by Jerry and Dominic Brandy, the company delivers neurotoxins, dermal fillers, laser skin resurfacing, laser hair removal and cosmetic surgery under CEO Eric Warden. Footbridge co-founder and Managing Partner David Rosner credited management and providers for the outcome. The incoming sponsor inherits a platform positioned for de novo openings and further M&A across the consolidating medical aesthetics market. (Link)

Venture Deals and Other

  1. MannKind Corporation (NASD: MNKD) raised approximately $50 million in a private placement led by Frazier Life Sciences. MannKind (NASD: MNKD) closed a roughly $50 million private placement with institutional investors, led by longstanding biotech investor Frazier Life Sciences. The company sold 10,440,838 common shares at $3.89 and pre-funded warrants for 2,412,632 shares at $3.88, with a $0.01 exercise price and no expiry. Proceeds fund general corporate purposes including a $45 million contingent value rights payment triggered by the FDA’s July 23, 2026 approval of Furoscix ReadyFlow for edema in heart failure and chronic kidney disease patients. (Link)
  2. Insight Partners led a $19 million Series A in AI-native provider credentialing platform Assured, with participation from First Round Capital and Kindred Ventures. Insight Partners led Assured’s $19 million Series A, joined by existing backers First Round Capital and Kindred Ventures, bringing total capital raised to $25 million following a $6 million seed in September 2025. Insight Managing Director Teddie Wardi articulated the thesis directly: incumbent credentialing tools function as systems of record while Assured’s agents perform the work itself, verifying data against more than 2,000 primary sources and cutting credentialing time by 30%. Launched in 2024, the NCQA-certified CVO serves over 100 organizations including Houston Methodist. Proceeds expand R&D and go-to-market teams ahead of a privileging product in early 2027. (Link)
  3. Brevy Care raised $4.77 million with participation from GreyMatter Capital to expand Medicaid reimbursement software for family caregivers. Brevy Care, a developer of software helping family caregivers access Medicaid reimbursements, raised $4.77 million in a round including San Francisco-based GreyMatter Capital, a mental and behavioral health-focused venture firm founded in 2021 that typically writes first checks of $250,000 to $1.2 million. The financing brings Brevy’s total capital raised to $4.92 million. GreyMatter’s thesis centers on early-stage innovation in behavioral healthcare delivery and adjacent care-navigation infrastructure. For investors, Brevy addresses a reimbursement-access gap in self-directed Medicaid programs, a payer-funded and demographically supported category as aging populations shift care burden toward unpaid family members. (Link)
  4. Sixth Street Growth led a $120 million Series D in autonomous revenue cycle management platform Candid Health, with participation from Oak HC/FT, 8VC and Y Combinator. Candid Health raised $120 million led by Sixth Street Growth, the dedicated growth platform of Sixth Street, which manages over $135 billion and has invested more than $13 billion across 90-plus companies. Oak HC/FT, 8VC and Y Combinator participated. The round marks a 3x valuation increase over the February 2025 Series C led by Oak HC/FT. Managing Director Alex Katz cited diligence calls with nearly 40 customers and proof points applying agentic AI at scale. Candid reported 190% year-over-year annual contracted run-rate growth and 180% net dollar retention in 2025, targeting the $280 billion US RCM spend. (Link)
  5. Innovation Endeavors and Xora co-led a $21 million Series A in sensor developer Elio, with participation from Kevin Weil, Scribble VC, UpWest and Resolute Ventures. Elio, a Silicon Valley and Israel-based company building sensors designed for artificial intelligence rather than human vision, raised $21 million co-led by Innovation Endeavors and Xora. Kevin Weil and Scribble VC participated, alongside existing investors UpWest and Resolute Ventures, who led the prior round. Total funding reaches $29 million. Founded by former Meta AR/VR executives, Elio embeds computation directly into optics using dynamic micromirror layers that behave like a neural network, letting AI decide what to capture in real time. Investors are backing applications spanning microscopy, semiconductor inspection, robotics and defense drone detection. (Link)
  6. 7wire Ventures and Allumia Ventures co-led an oversubscribed $16.2 million Series A in Karoo Health, joined by First Trust Capital Partners, SpringRock Ventures and Hyde Park Angels. Karoo Health, an Albuquerque, New Mexico cardiovascular technology company led by CEO Ian Koons, closed a $16.2 million oversubscribed Series A co-led by 7wire Ventures and Allumia Ventures, with First Trust Capital Partners, SpringRock Ventures and Hyde Park Angels participating. Managing Partners Lee Shapiro of 7wire and Jeff Stolte of Allumia join the board. Deployed programs have produced independently analyzed reductions exceeding 40% in emergency department visits and inpatient admissions, plus a greater than 10% total cost of care reduction. Karoo supports 600-plus cardiology providers across 11 states; proceeds fund predictive models and health plan expansion. (Link)
  7. FUSE led a $16 million financing in AI-powered concierge primary care platform Prosper Medical, with participation from Aurum Partners, Better.vc, Cal Innovation Fund, Fluent, Latitude Capital, Knoll Ventures and WTI. Prosper Medical, a San Francisco company founded in 2026 by CEO Ryan McQuaid and CMO James Wantuck, MD, raised $16 million led by FUSE alongside Aurum Partners, Better.vc, Cal Innovation Fund, Fluent, Latitude Capital, Knoll Ventures and Western Technology Investment. Investors are backing repeat founders who previously built PlushCare and sold it to Accolade for $450 million. Unlike cash-pay concierge peers, Prosper is in-network with major insurance plans across all 50 states at a $69 monthly membership, using an AI care layer for longitudinal data aggregation and referral coordination. Proceeds expand the physician network and enter new markets. (Link)
  8. Decathlon Capital Partners provided a non-dilutive growth-debt investment to value-based care technology company Health Endeavors. Decathlon Capital Partners, a growth-debt provider with offices in Palo Alto and Park City, made a strategic investment in Health Endeavors, a Farmington, Utah technology partner to Accountable Care Organizations. Deal size was undisclosed, but the structure requires no dilution of existing shareholders. Managing Director Matt Hoffman framed the investment as conviction in value-based care economics. Health Endeavors serves over 2 million patients with 16-plus years of ACO experience and partnerships with Novant Health and Providence. Decathlon targets companies with $4 million to $100 million revenue, 10%-plus growth and near-term visibility to cash-flow-positive status, avoiding equity dilution and loss of control. (Link)
  9. Vensana Capital and Ohio-based Mutual Capital Partners co-led a $30 million Series A in TYBR Health, with participation from Neovate Capital Partners and existing investors. TYBR Health, a Houston, Texas orthopedic biologics company co-founded and led by CEO Tim Keane, PhD, raised $30 million in Series A financing co-led by Vensana Capital and Mutual Capital Partners, the Cleveland, Ohio venture firm managed by Bill Trainor and Wayne Wallace that invests exclusively in Midwest healthcare IT and medical device companies. Proceeds expand commercial access to the FDA-cleared B3 GEL System, a flowable extracellular matrix hydrogel, broaden indications and fund clinical studies on tissue protection during orthopedic surgery. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update May 11th, 2026

LECO_Weekly-Healthcare-News_5-11-2026Download
  1. Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease Angelini Pharma S.p.A., an international pharmaceutical company and part of Italy’s Angelini Industries Group, entered into a definitive agreement to acquire Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), a Coral Gables, FL-based commercial-stage biopharmaceutical company focused on rare and difficult-to-treat diseases, in an all-cash transaction valued at approximately $4.1 billion or $31.50 per share. The deal, announced May 7, 2026, represents a premium to Catalyst’s recent trading prices and will expand Angelini Pharma’s U.S. market presence and rare-disease portfolio, particularly in brain health and neurological conditions. Closing is expected in the third quarter of 2026, subject to Catalyst stockholder approval, regulatory clearances, and other customary conditions. (Link)
  2. Roche Holding AG (SIX: RO, ROP; OTCQX: RHHBY), the Swiss pharmaceutical and diagnostics giant, entered into a definitive merger agreement to acquire PathAI, a Boston-based AI-powered digital pathology company, for USD 750 million upfront plus up to USD 300 million in milestone payments, valuing the deal at up to USD 1.05 billion. Roche (SIX: RO, ROP; OTCQX: RHHBY) has signed a definitive merger agreement to acquire Boston-based digital pathology firm PathAI. Under the terms of the agreement, Roche will pay a purchase price of USD 750 million upfront and additional milestone payments of up to USD 300 million, bringing total potential consideration to USD 1.05 billion. Roche has partnered with the company since 2021, expanding their agreement in 2024 to include the development of AI-enabled companion diagnostic algorithms. Roche Diagnostics will absorb PathAI as an operating unit after closing expected in H2 2026, pending regulatory clearance, accelerating Roche’s AI-powered diagnostics capabilities. (Link)
  3. Cross Country Healthcare, Inc. (NASD: CCRN), a Boca Raton-based technology-driven healthcare workforce solutions company, entered into a definitive agreement to be acquired by growth-oriented private equity firm Knox Lane in an all-cash transaction valued at approximately $437 million, or $13.25 per share. Cross Country Healthcare (NASDAQ: CCRN) has signed a definitive agreement to be taken private by Knox Lane, a growth-oriented investment firm, in an all-cash transaction valued at $437 million, or $13.25 per share. The price represents a premium of approximately 31% to CCRN’s closing price on May 6, 2026, and a 45% premium to its 90-day volume-weighted average trading price. Knox Lane is a private equity firm with $3.5 billion in assets under management. Upon completion, Cross Country Healthcare will become a privately held platform company in Knox Lane’s portfolio and will cease trading on Nasdaq, with closing expected in Q3 2026.  (Link)
  4. Sanford Health, a Sioux Falls, South Dakota-based nonprofit rural health system, and North Memorial Health, a Twin Cities-based Minnesota nonprofit health system, signed a definitive agreement to combine into a single nonprofit organization, supported by a planned $600 million investment. Sanford Health and North Memorial Health have signed a definitive agreement to combine into a single nonprofit health system. The transaction includes a $600 million investment in Twin Cities services. Sanford’s most recent annual revenue was nearly $11.7 billion in 2025, which reflects its merger with Marshfield Clinic Health System in Wisconsin. Sanford Health President and CEO Bill Gassen will continue to serve as president and chief executive officer of the combined organization. The partnership is expected to close sometime this year, subject to completion of regulatory processes and other customary closing conditions. (Link)
  5. The University of Pittsburgh Medical Center (UPMC), a Pittsburgh-headquartered nonprofit health care provider and insurer, and CommonSpirit Health, one of the nation’s largest nonprofit Catholic healthcare organizations, signed a definitive agreement transferring ownership of Steubenville, Ohio-based Trinity Health System to UPMC. UPMC and CommonSpirit Health have signed a definitive agreement transferring ownership of Trinity Health System to UPMC. The transfer includes Trinity West, Trinity East, Trinity St. Clairsville Neighborhood Hospital, Trinity Twin City Medical Center, and associated clinics, to UPMC. The transaction is expected to be completed in Fall 2026, pending regulatory review and customary closing conditions. The deal will allow UPMC to expand into the Midwest from its foothold in the mid-Atlantic. Financial terms were not disclosed. The deal marks UPMC’s first expansion into Ohio while supporting CommonSpirit’s multiyear asset-divestiture turnaround strategy. (Link)
  6. agilon health, inc. (NYSE: AGL), an Austin, TX-based value-based care platform partnering with primary care physicians on Medicare Advantage, saw its stock surge after delivering Q1 2026 revenue of $1.42 billion and GAAP EPS of $1.80, prompting upgrades from Deutsche Bank and Jefferies. agilon health (NYSE: AGL) shares surged sharply following a Q1 2026 earnings beat. Revenue came in at $1.42 billion versus analyst estimates of $1.38 billion, EPS (GAAP) of $1.80 crushed the consensus of $0.83, and Adjusted EBITDA of $53.84 million beat estimates of $36.15 million by nearly 49%. Deutsche Bank upgraded agilon health’s stock rating to Buy from Hold, raising its price target to $49.00, while Jefferies also upgraded the stock to Buy. For the full year, the company raised its 2026 Adjusted EBITDA guidance to $10–$40 million, with new CEO Tim O’Rourke commencing leadership. (Link)
  7. Addus Enters Indiana With HomeCourt Acquisition, Lines Up Second Deal Addus HomeCare Corporation (NASDAQ: ADUS), a Frisco, Texas-based provider of home and community-based personal care services, acquired HomeCourt Home Care, a Fort Wayne, Indiana-based non-medical home care agency. Addus HomeCare has entered the Indiana market through the acquisition of HomeCourt Home Care. The deal adds approximately $9.8 million in annualized revenue and expands Addus’ footprint into the Midwest with a strong regional provider of in-home personal care and supportive services for elderly and disabled clients. The transaction closed on May 1, 2026 and marks Addus’ continued geographic expansion strategy in the home-care sector. Financial terms were not disclosed. (Link)
  8. HealthVerity, Inc., a Philadelphia-based leader in privacy-protected real-world data exchange and patient identity solutions, entered into a definitive agreement to acquire Symphony Health Solutions Corporation, a commercial healthcare data and analytics business formerly part of ICON plc (NASDAQ: ICLR). HealthVerity has announced the acquisition of Symphony Health to combine its clinical data depth with Symphony’s commercial insights, creating a unified, AI-ready platform for life sciences, payers, and government entities. The transaction, announced on May 5, 2026, is expected to close in May 2026 subject to customary closing conditions. Financial terms were not disclosed. (Link)
  9. Elsevier completes acquisition of Mytonomy and introduces comprehensive end to end patient engagement solutions for healthcare providers. Elsevier, a global leader in scientific publishing and health information solutions (part of RELX plc), completed the acquisition of Mytonomy, Inc., a Washington, D.C.-based provider of cloud-based video patient engagement and education platforms for hospitals and health systems. Elsevier has completed the acquisition of Mytonomy to integrate its clinical content libraries with Mytonomy’s video-first patient engagement platform, creating end-to-end solutions that improve adherence, reduce readmissions, and support value-based care across the care continuum. The deal, closed on May 5, 2026, combines Elsevier’s trusted evidence-based content with Mytonomy’s HIPAA-compliant, personalized video and interactive tools already deployed at more than 300 U.S. healthcare organizations. Financial terms were not disclosed. (Link)
  10. CQ Medical, the Avondale, Pennsylvania-based global leader in radiotherapy positioning solutions formed in 2022 through the combination of CIVCO Radiotherapy and Qfix, acquired .decimal, a Sanford, Florida-based precision manufacturer of patient-specific radiotherapy beam-shaping devices. CQ Medical has acquired .decimal to expand its patient-specific cancer treatment portfolio. CQ Medical was formed in 2022 through the combination of CIVCO Radiotherapy and Qfix, bringing together decades of expertise in essential radiation therapy positioning and immobilization solutions. Serving the radiotherapy clinical community for more than 40 years, .decimal is a trusted partner known for its rapid production of customized, patient-specific devices—typically manufactured and shipped within 1–2 days of order receipt. To date, the company has delivered over 500,000 patient-specific treatment devices, and actively serves more than 900 cancer centers across the United States. Financial terms were not disclosed. (Link)
  11. Med Tech Solutions (MTS), a Valencia, California-based managed healthcare IT services provider and portfolio company of Silversmith Capital Partners, acquired Avarion (formerly Huntzinger Management Group), a two-time Best in KLAS healthcare IT advisory firm, to span the full care continuum. Silversmith Capital Partners-backed Med Tech Solutions has acquired Avarion to strengthen its managed services platform. Med Tech Solutions, a provider of managed healthcare IT services and a portfolio company of Silversmith Capital Partners, acquired Avarion, a healthcare IT advisory firm serving hospitals, health systems and care networks. The combination unites MTS’ EHR managed services, application support, and technology infrastructure expertise with Avarion’s deep experience in healthcare IT advisory, consulting, and leadership services. Robert Kitts, Avarion’s CEO and founding partner, will report to Mona Abutaleb, CEO of MTS, and lead the company’s strategic advisory and staffing services. Financial terms were not disclosed. (Link)
  12. TimelyCare, a Fort Worth, TX-based virtual care provider for higher education serving nearly 500 campuses nationwide, acquired Alongside, a clinician-designed AI coaching platform trusted by more than 200 schools, to expand its student support model with continuous early-intervention AI coaching. TimelyCare has acquired Alongside, a clinician-designed AI coaching platform for students. Alongside combines evidence-based skill-building with proprietary safety models that detect risk and connect students to additional support when needed. Trusted by nearly 500 campuses across the U.S., TimelyCare combines URAC-accredited clinical standards with a measurement-based approach, while Alongside is trusted by more than 200 schools nationwide. The acquisition expands TimelyCare’s approach beyond traditional points of clinical need, positioning the company to engage a broader student population earlier and more consistently across the care continuum. Financial terms were not disclosed. (Link)
  13. Xpress Wellness, a Goldman Sachs-backed Oklahoma City-based provider of urgent care, virtual primary care, occupational medicine, behavioral health and post-acute services, acquired Midwest Counseling Services, a Wichita, Kansas-based mental health clinic founded in 2022 serving older adults in senior communities. Goldman Sachs-backed Xpress Wellness has acquired Wichita-based Midwest Counseling Services. Founded in 2022, Midwest Counseling Services provides mental health services to older adults living in senior communities through approaches including talk therapy and individual counseling. Xpress Wellness is an Oklahoma City-based provider of urgent care, virtual primary care, occupational medicine, behavioral health and post-acute services across rural and suburban communities. Lisa Harrison, founder of Midwest Counseling Services, now serves as Xpress Wellness’ Director of Operations of Post-Acute overseeing the Kansas market, with the deal expanding the acquirer’s behavioral health footprint in Kansas and adjacent states. (Link)
  14. Pediatrica Health Group, a Miami-based multi-site pediatric primary care platform backed by M33 Growth, acquired the long-established Westchester, Miami-Dade pediatric practice of Dr. Juan Ruiz-Unger to expand equitable access to care amid rising regional population growth. Pediatrica Health Group, backed by Boston-based venture and growth-stage investor M33 Growth, has acquired an additional pediatric practice in the Westchester neighborhood of Miami-Dade County. For over 40 years, Dr. Juan Ruiz-Unger has delivered compassionate, evidence-based care to Westchester families. Roberto Palenzuela, Chief Executive Officer of Pediatrica Health Group, said the acquisition aligns with the company’s goal of supporting physicians who want to expand access while maintaining continuity of care within their communities. Financial terms were not disclosed. The deal continues Pediatrica’s multi-site pediatric primary care roll-up strategy across South Florida. (Link)
  15. SpinLife, a Columbus, Ohio-based omni-channel mobility and home accessibility retailer owned by Brentwood, Tennessee-based Complex Rehab Technology leader Numotion, acquired Triton Medical and opened a new SpinLife retail store in Lady Lake, Florida, expanding its Central Florida footprint. Numotion-owned SpinLife has acquired Triton Medical and launched a new Central Florida retail location. SpinLife, owned by Numotion, said in a May 5 announcement that the acquisition was completed on April 22. The retail location is now operating as SpinLife — Lady Lake and strengthens the company’s presence in central Florida and enhancing service to the growing Lady Lake and The Villages communities. Matt Chesshire, Triton Medical’s founder, will remain at the Lady Lake store as general manager. Numotion acquired SpinLife in 2021. Financial terms were not disclosed. (Link)
  16. Care Advantage, Inc., a Mid-Atlantic-based privately held home care provider, announced the acquisition of First Priority Home Care, a Columbia, South Carolina-based non-medical home care agency, advancing its targeted expansion strategy across the Mid-Atlantic and Southeast. Care Advantage, Inc. has acquired Columbia, South Carolina-based First Priority Home Care. Care Advantage, one of the Mid-Atlantic’s largest privately held home care providers, today announced the acquisition of First Priority Home Care, based in Columbia, South Carolina. This latest transaction marks another step in Care Advantage’s continued expansion into the southern United States. First Priority Home Care is a non-medical home care agency based in Columbia, South Carolina, providing in-home support services to seniors and adults who need assistance. Financial terms of the deal were not disclosed. (Link)
  17. Standard Dental Labs Inc., (OTCQB:TUTH) an Orlando-based publicly traded dental laboratory consolidator, completed the acquisition of BRLIT Dental Laboratory, a Sarasota, Florida-based dental lab founded in 1977, adding approximately $886,000 in annual revenue. Standard Dental Labs Inc. (OTCQB: TUTH) has completed the acquisition of BRLIT Dental Laboratory in Sarasota, Florida. The transaction adds approximately $886,000 in annual revenue to Standard Dental Labs’ existing revenue base of approximately $236,000, bringing the company’s total annualized revenue to more than $1.1 million. The company holds a market capitalization of $6.54 million. BRLIT Dental Laboratory, founded in 1977, has served dentists throughout Florida for nearly five decades, and the acquisition expands the buyer’s footprint along Florida’s Gulf Coast. The company intends to continue pursuing strategic acquisitions in Florida’s dental laboratory industry. (Link)
  18. TopGum Industries Ltd. (TASE: TPGM), an Israel-based global leader in gummy-format dietary supplements, completed the acquisition of the U.S. gummy manufacturing operations of P&L Developments LLC, a Westbury, New York-based pharmaceutical and consumer healthcare CDMO, in a transaction valued at up to USD 35 million. TopGum Industries Ltd. (TASE: TPGM) has completed its acquisition of P&L Developments’ U.S. gummy manufacturing operations. The consideration, funded by TopGum’s existing resources, comprises US$10 million in cash at closing, 1,893,060 shares valued at approximately US$8 million at closing (based on a price of NIS 13 per share), and up to 4,022,751 additional shares (valued at up to US$17 million) as contingent consideration, payable upon achievement of agreed commercial and regulatory milestones.  (Link)
  19. Arete Health Announces Acquisitions of Virginia Rehabilitation & Wellness and Summerville Physical Therapy & Balance for Adults Arete Health, a physician-led multi-specialty practice management platform, acquired Virginia Rehabilitation & Wellness and Summerville Physical Therapy & Balance for Adults, two established physical therapy practices in Virginia. Arete Health has completed the acquisition of two Virginia-based physical therapy practices—Virginia Rehabilitation & Wellness and Summerville Physical Therapy & Balance for Adults—on May 5, 2026. The deals strengthen Arete’s outpatient rehabilitation footprint in the Mid-Atlantic and add specialized orthopedic, sports medicine, and balance therapy services. The combined practices serve several hundred patients weekly across multiple locations. Financial terms were not disclosed. (Link)

Venture Deals and Other

  1. Basata, a Phoenix-based AI company building the operational layer for U.S. healthcare, raised a $21 million Series A led by Basis Set Ventures with participation from Cowboy Ventures, PHX Ventures, Zenda Capital, and Victoria Treyger, bringing total funding to $24.5 million. Basata has closed a $21 million Series A funding round to scale its AI-driven healthcare administrative automation platform. The Series A was led by Basis Set Ventures, with participation from Cowboy Ventures, PHX Ventures, Zenda Capital, and Victoria Treyger. The round brings total funding to $24.5 million. Basis Set Ventures’ Lan Xuezhao led the round, joined by Cowboy Ventures’ Aileen Lee, PHX Ventures, Zenda Capital, and Victoria Treyger. The company has served more than 500,000 patients to date, including 100,000 patients during the past month alone, while working with specialty groups across cardiology, urology, gastroenterology, and ophthalmology. (Link)
  2. Dandelion Health, a New York-based clinical intelligence platform serving life sciences, raised a $14 million Series A led by Healthier Capital with participation from Colle Capital and existing investors Primary Venture Partners, Moxxie Ventures, and Convergent Ventures, to scale its multimodal clinical AI infrastructure. Dandelion Health has secured $14 million in Series A funding. Healthier Capital led the round, with participation from Colle Capital and existing investors Moxxie Ventures, Convergent Ventures and Primary Venture Partners. Built on a network spanning 73 hospitals and more than 15 million patients, Dandelion is unique in its ability to combine structured data — electronic medical records and claims — with unstructured clinical text and raw biological signals including ECG waveforms, echocardiogram videos, radiology imaging, pulmonary function tests, and ultrasound. The Series A financing will be used to expand Dandelion’s pharmaceutical partnerships, scale the company’s data and engineering infrastructure, and grow commercial and scientific teams. (Link)
  3. Enzo Health, a Lehi, Utah-based AI-driven platform for home health and post-acute care launched in 2024, raised a $20 million Series A led by global venture capital firm N47 with participation from existing investors Gradient (a Google-affiliated investment firm), Tandem Ventures, and Rigby Watts, bringing total funding to $26 million. Enzo Health has raised a $20 million Series A funding round. The round was led by N47, bringing the company’s total funding to $26M. Existing investors Gradient, Tandem Ventures, and Rigby Watts also participated. Existing investors Gradient (Palo Alto, a Google-affiliated investment firm), Tandem Ventures (Draper, UT), and Rigby Watts (Millcreek, UT) also participated. Launched in 2024, Enzo Health has grown revenue by more than 40X in twelve months and is now used by organizations that support over 500,000 patients annually. The funds will accelerate expansion into skilled nursing and hospice sectors. (Link)
  4. Travv, a Stillwater, Oklahoma-based AI-native diagnostic platform for veterinary medicine led by founder and CEO Derick Whitley, DVM, DACVP, closed a $1.6 million seed funding round led by Digitalis Ventures with participation from AniVC, to advance its cloud-based veterinary diagnostic platform. Travv has closed a $1.6 million seed funding round. Travv, a Stillwater, OK-based provider of an AI-native diagnostic platform for veterinary medicine, closed a $1.6m seed funding round. The round was led by Digitalis Ventures, with participation from AniVC. The funding will support continued development of Travv’s AI-native diagnostic platform for veterinary medicine, including product expansion, hospital onboarding, commercial growth, and key integrations. Digitalis Ventures backs founders solving critical problems in health. The firm invests in early-stage companies across life sciences, health technology & services, and animal health, while AniVC focuses on early-stage pet companies. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update May 4th, 2026

LECO_Weekly-Healthcare-News_5-4-2026Download
  1. UCB (ENX:UCB) to acquire clinical-stage biotech Candid Therapeutics for up to $2.2 billion to expand its immunology pipeline with novel T-cell engagers UCB has entered into a definitive agreement to acquire Candid Therapeutics for $2 billion in upfront payments and up to $200 million in potential development milestones. The transaction, which hijacks Candid’s planned reverse merger with Rallybio, brings a pipeline of T-cell engagers (TCEs) led by cizutamig (BCMAxCD3), a Phase 1/2-ready bispecific antibody demonstrating deep B-cell and plasma cell depletion with manageable safety in autoimmune patients. This deal positions UCB to compete directly in the emerging TCE autoimmune field alongside Gilead, accelerating its strategy in high-unmet-need immune-mediated diseases through off-the-shelf, outpatient-compatible therapies. Candid’s additional assets, including a CD20xCD3 bispecific and preclinical trispecific TCEs, further strengthen UCB’s next-generation immunology platform. (Link)
  2. Chiesi Group to acquire KalVista Pharmaceuticals (NASD:KALV) for approximately $1.9 billion to strengthen its global rare disease portfolio Chiesi Group has entered into a definitive agreement to acquire KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) for $27.00 per share in cash, representing an equity value of approximately $1.9 billion. The transaction, Chiesi’s largest acquisition to date, adds EKTERLY® (sebetralstat), the first oral, on-demand plasma kallikrein inhibitor for hereditary angioedema (HAE) attacks in patients 12 years and older. Already approved in the U.S., EU, UK, Japan, and other markets with strong commercial uptake ($49 million in 2025 U.S. sales), sebetralstat will bolster Chiesi Global Rare Diseases’ immunology franchise and support the group’s 2030 revenue target of €6 billion. The deal is expected to close in Q3 2026, subject to customary closing conditions including a successful tender offer. (Link)
  3. Atrium Health and WakeMed propose $2 billion strategic combination to expand services and create 3,300 jobs in North Carolina Atrium Health (part of Advocate Health) and Raleigh-based WakeMed have announced a proposed merger that includes a $2 billion investment in Wake County, aimed at expanding access across North Carolina and creating approximately 3,300 new healthcare jobs over five years. The combination would unite North Carolina’s largest health system with the Triangle’s leading community-based provider, enhancing specialty services (cancer, neurosciences, pediatrics), building the state’s largest nonprofit mental health network (>360 inpatient beds), and establishing its largest virtual care platform. Key initiatives include redevelopment of WakeMed’s Raleigh campus, hospital expansions, new Healthplex facilities, and strengthened medical education partnerships with Wake Forest University School of Medicine. The non-binding proposal requires approval from the Wake County Board of Commissioners and is subject to regulatory review. (Link)
  4. CareDx (NASD: CDNA) to acquire Naveris for $160 million upfront plus up to $100 million in milestones to enter viral-mediated cancer MRD surveillance CareDx, Inc. has entered into a definitive agreement to acquire Naveris, a commercial-stage precision oncology diagnostics company specializing in blood-based molecular residual disease (MRD) monitoring for HPV-driven cancers. The transaction includes $160 million in upfront cash consideration and up to an additional $100 million contingent on revenue milestones. Naveris’ flagship NavDx® test, based on proprietary Tumor Tissue Modified Viral (TTMV®) DNA technology, is Medicare-reimbursed and addresses a $4.5 billion total addressable market in head and neck, anal, and other viral-mediated cancers. The company generated approximately $34 million in unaudited 2025 revenue (with Q1 2026 revenue of ~$12 million at 65% gross margin) and has performed over 130,000 commercial tests to date. The acquisition extends CareDx’s precision medicine strategy from transplant diagnostics into specialty oncology while remaining neutral to 2026 Adjusted EBITDA guidance. The deal is expected to close in Q3 2026. (Link)
  5. CareMetx expands its patient access platform through the strategic acquisition of U.S.-based patient services and TheraCom free goods pharmacy operations from Cencora, Inc. (NYSE: COR) CareMetx has successfully completed the acquisition of Cencora’s (COR) U.S. Hub consulting services and its TheraCom pharmacy business to create a more robust technology-enabled services platform. This transaction integrates Cencora’s extensive staffing and pharmacy infrastructure with CareMetx’s AI-driven workflow automation. The deal positions CareMetx to serve over 155 pharmaceutical brands, focusing on reducing treatment barriers and improving patient access to specialty medications. Cencora will transition into a preferred partner role, ensuring a seamless transition for existing clients while leveraging CareMetx’s specialized digital solutions to enhance patient journeys across the healthcare ecosystem. (Link)
  6. Odyssey Therapeutics targets up to $810 million valuation in Nasdaq IPO for autoimmune and inflammatory disease pipeline Odyssey Therapeutics has filed to raise up to $238.3 million in its U.S. initial public offering by offering 13.2 million shares priced between $16 and $18 each, targeting a valuation of up to $809.9 million. The Boston-based biopharmaceutical company is developing precision therapies for autoimmune and inflammatory diseases, with lead candidate OD-001 in a mid-stage (Phase 2) trial for ulcerative colitis. Odyssey plans to list on Nasdaq under the ticker “ODTX,” with J.P. Morgan, TD Cowen, and Cantor serving as lead underwriters. The IPO comes amid a strong resurgence in biotech listings and would provide capital to advance its clinical pipeline in high-unmet-need immune-mediated indications. (Link)
  7. Infinite Epigenetics acquires Tally Health a longevity company co-founded by Dr. David Sinclair, seeded by L Catterton, to build a vertically integrated epigenetic testing platform Infinite Epigenetics has completed the acquisition of Tally Health, marking a major consolidation in the longevity and biological age testing market. The deal combines Tally Health’s consumer-facing brand and TallyAge™ test with Infinite Epigenetics’ scientific infrastructure and DNA methylation datasets. Tally Health will operate as a standalone consumer brand within the Infinite Epigenetics ecosystem, gaining access to advanced diagnostic tools from the TruDiagnostic arm. The acquisition is intended to accelerate the development of personalized interventions for aging and shift the healthcare focus toward proactive longevity. L Catterton, an initial investor in Tally, sees the exit as a milestone in the commercialization of biological age metrics. (Link)
  8. Global clinical research organization Parexel acquires Vitrana to integrate its AI-powered pharmacovigilance platform into Parexel’s comprehensive patient safety and clinical development services Parexel has bolstered its patient safety capabilities through the acquisition of Vitrana, a provider of AI-driven pharmacovigilance technology. The deal allows Parexel to offer an end-to-end safety model that automates data processing for regulatory submissions, reducing the administrative burden on clinical trials. Vitrana’s system-agnostic platform will be integrated into Parexel’s global infrastructure, enabling pharmaceutical clients to achieve greater accuracy in adverse event reporting. This strategic move aims to improve operational efficiency and global compliance while maintaining a focus on high-quality clinical outcomes. Vitrana will operate as a Parexel company, keeping its leadership team to drive continued technological innovation. (Link)
  9. Enterprise oncology platform Azra AI acquires Thynk Health to expand its AI-driven incidental findings and lung cancer screening platform across 500 hospitals Azra AI has acquired Thynk Health to create a unified platform for managing incidental medical findings and cancer screenings. The merger brings together two leaders in the oncology workflow space, serving a combined customer base that includes five of the top ten U.S. health systems. By integrating Thynk Health’s specific expertise in lung cancer screening, Azra AI enhances its ability to identify and track patients from the moment a potential issue is spotted in imaging. The combined entity aims to eliminate patient handoff failures and accelerate the diagnosis of life-threatening conditions. Thynk Health’s leadership will join Azra AI to oversee the expansion of the incidental findings platform. (Link)
  10. Quality data management leader Medisolv, Inc. acquires Health Elements AI to enhance its automated data abstraction and clinical registry reporting capabilities for healthcare organizations Medisolv has acquired Health Elements AI to modernize its clinical data extraction processes using advanced artificial intelligence. The acquisition targets the labor-intensive process of manual chart reviews, aiming to support the 4,000 abstracters using Medisolv’s platform across 1,800 hospitals. By integrating Health Elements’ AI-first software, Medisolv enhances its ability to capture structured data for critical reporting to organizations like the American Heart Association. This move follows Medisolv’s recent acquisition of Lilac Software, reinforcing its commitment to reinventing quality data usage. The combined technology will help healthcare providers transition more effectively to value-based care models by improving data accuracy and reducing staff burden. (Link)
  11. Pinnaql acquires Pharma Resource Group to expand scientific, formulation, and manufacturing advisory capabilities Pinnaql, Inc., a 3 Boomerang Capital portfolio company, has acquired Pharma Resource Group, Inc. (PRG), a provider of analytical sciences, formulation development, scientific writing, manufacturing, and change control advisory services to the pharmaceutical and life sciences industries. This marks Pinnaql’s third tuck-in acquisition in the past 10 months and significantly strengthens its end-to-end offering across the product lifecycle — from laboratory innovation and scale-up to validation, quality systems, regulatory compliance, and commercial readiness. Founded in 2007, PRG brings deep formulation and manufacturing expertise that complements Pinnaql’s existing strengths in engineering, validation, and quality consulting. The deal advances Pinnaql’s strategy to build a scaled, multi-disciplinary advisory platform serving biopharma, medical device, and CDMO clients. (Link)
  12. UConn Health signs letters of intent to acquire Bristol Hospital and Day Kimball Hospital as part of statewide expansion UConn Health has signed letters of intent to acquire Bristol Health (anchored by 154-bed Bristol Hospital) and Day Kimball Hospital (104-bed facility in Putnam), advancing its strategy to build a broader community hospital network across Connecticut. The non-binding agreements aim to close the Bristol transaction by January 2027 and the Day Kimball deal by fall 2026, subject to regulatory approval via the state’s Certificate of Need process. Both independent community hospitals have faced financial challenges, with negative operating margins in recent years, and the affiliations are expected to provide financial stability, expand access to academic medical center expertise, and strengthen UConn Health’s competitive position. The moves follow UConn’s recent acquisition of Waterbury Hospital and align with state-supported efforts to preserve essential healthcare services in the region. (Link)
  13. Nationwide Medical acquires Dynamic Healthcare Services (DHS) to expand home respiratory and durable medical equipment footprint Nationwide Medical, a leading provider of specialized respiratory care and home healthcare solutions, has acquired Dynamic Healthcare Services (DHS), a well-established provider of home respiratory supplies, durable medical equipment (DME), and oxygen therapy products serving Pennsylvania, New Jersey, and surrounding markets. The strategic acquisition strengthens Nationwide Medical’s regional presence and enhances its clinical programming for OSA, COPD, and other chronic respiratory conditions through DHS’s patient-centric model and strong local clinician relationships. This transaction expands access to comprehensive home-based care, including sleep therapy support, patient monitoring programs, and advanced equipment, while integrating DHS’s expertise with Nationwide Medical’s national infrastructure and remote monitoring capabilities. The deal aligns with Nationwide Medical’s growth strategy focused on improving therapy compliance and patient outcomes in the home medical equipment sector. (Link)
  14. The Ensign Group (NASD: ENSG)  acquires real estate and expands operations in Texas with new post-acute care campus The Ensign Group, Inc. has acquired the real estate and operations of a newly constructed 124-bed skilled nursing and rehabilitation facility in Texas, marking its continued expansion in the state. This transaction adds a modern, purpose-built campus to Ensign’s portfolio and brings the total number of operating facilities in Texas to 52. The acquisition aligns with Ensign’s disciplined “pay-for-performance” model and its strategy of entering high-quality, well-located assets in attractive markets. Financial terms were not disclosed. This move further strengthens Ensign’s presence in one of its key growth states and supports its long-term goal of portfolio diversification and operational scale in the post-acute care sector. (Link)
  15. Baystate Health and Trinity Health Of New England sign definitive agreement for integration of Mercy Medical Center Baystate Health has entered into a definitive agreement with Trinity Health Of New England to transition ownership of Mercy Medical Center (a 182-bed acute care hospital in Springfield, MA), its joint venture affiliates, and medical group entities to Baystate Health, subject to regulatory approvals. The transaction will allow Baystate to preserve Mercy’s nonprofit mission and Catholic legacy while providing financial stability and operational support to ensure long-term sustainability of high-quality local care in Western Massachusetts. Trinity Health Of New England will retain ownership of its Brightside for Families and Children services as well as continuing care operations, including Mercy LIFE, Beaven Kelly Home, and Saint Luke’s Home. The move addresses Mercy’s ongoing financial pressures from reimbursement challenges, outpatient shifts, and staffing shortages, strengthening regional access and positioning Baystate as a stronger safety-net provider for the Pioneer Valley. (Link)
  16. AI automation firm 1520ai acquires data insights firm Hospice Analytics to combine hospice-native artificial intelligence with established market utilization datasets. 1520ai has finalized the acquisition of Hospice Analytics, a firm with 20 years of experience in hospice data analysis. The merger unites 1520ai’s predictive modeling with Hospice Analytics’ deep market trends and utilization data to create a new platform focused on regulatory compliance and clinical quality. 1520ai, which has minority backing from simPAL Solutions, plans to use the acquisition to provide hospice providers with real-time answers to operational and financial questions. Hospice Analytics will maintain its branding and its partnership with the National Hospice Locator. (Link)
  17. Superior Health Holdings a Renovus Capital Partners portfolio company, acquires Chant Healthcare to expand its home health and hospice services into the Oklahoma market Superior Health Holdings has expanded into Oklahoma through the acquisition of Chant Healthcare, which operates as Compassion Homecare and Sans Bois Hospice. Backed by Renovus Capital Partners, Superior intends to leverage Chant’s strong presence in 11 Oklahoma counties and its large dual-eligible Medicaid patient base. The acquisition provides a strategic foothold for further expansion into the Oklahoma City and Tulsa markets. Chant Healthcare’s leadership will remain in place to manage local operations while utilizing Superior’s broader administrative and clinical infrastructure. This transaction marks Superior’s entry into its second state, following its established presence in Arkansas, and focuses on scaling rural healthcare delivery through specialized hospice services. (Link)
  18. The Medical University of South Carolina and Revival Healthcare Capital establish a five-year strategic innovation partnership to fund and scale next-generation medical technology solutions The Medical University of South Carolina (MUSC) has entered into a five-year partnership with private equity firm Revival Healthcare Capital to accelerate the commercialization of medical device innovations. Under the agreement, MUSC will provide clinical expertise and validation support for Revival’s portfolio companies, while Revival will provide the capital and operational leadership necessary to scale MUSC-originated technologies. This collaboration is designed to bridge the gap between academic research and commercial medical solutions. The partnership focuses on identifying unmet clinical needs and deploying high-impact medical devices into the healthcare market. Both organizations aim to create a repeatable model for innovation that improves patient outcomes through targeted investment and clinical rigor. (Link)

Venture Deals and Other

  1. DTC health platform Musely secures $360 million in non-dilutive capital from General Catalyst to accelerate customer acquisition for its dermatology and menopause care lines Musely has secured a $360 million capital commitment from General Catalyst through a non-dilutive financing structure. This arrangement allows Musely to fund aggressive marketing and customer acquisition efforts without giving up equity in the company. The funding will primarily support Musely’s core prescription skincare business and its recent expansion into the menopause care market. By utilizing non-dilutive capital, Musely maintains control over its operations while leveraging General Catalyst’s resources to scale its digital platform. The deal highlights a growing trend of high-growth, profitable direct-to-consumer health companies choosing creative financing over traditional venture rounds to fuel expansion. Musely plans to use the funds to reach millions of new patients globally. (Link)
  2. Bio-inspired BCI startup Axoft secures $55 million in Series A funding led by C.P. Group Innovation, with participation from Hillhouse Investment and Gaorong Ventures Axoft has raised $55 million in an oversubscribed Series A round to advance its implantable brain-computer interface (BCI) technology. The round, led by C.P. Group Innovation, included participation from Hillhouse, Gaorong, and the Stanford President’s Venture Fund, bringing Axoft’s total funding to over $60 million. Axoft is developing bio-inspired, soft implants that aim to provide long-term stability for neural communication without damaging brain tissue. The funding will support the expansion of global clinical trials, including the company’s first-in-human studies. This investment underscores the high demand for scalable BCI solutions that can treat neurological disorders. Axoft intends to use the capital to navigate regulatory approvals and scale its manufacturing capabilities. (Link)
  3. Truentity Health secures $35 million in oversubscribed Series A funding led by Evidenced VC, with participation from K-Street Capital, Cofounders Capital, and Tweener Fund. Truentity Health has closed a $35 million Series A round to scale its pharmacy-led clinical care model, which enables community pharmacies to provide chronic disease management services. The investment was led by Evidenced VC and saw participation from regional investors like Cofounders Capital and Tweener Fund. Truentity provides an AI platform that supports pharmacies in delivering reimbursable services such as remote patient monitoring and medication therapy management. The capital will be used to expand the company’s network into new state markets throughout 2026. By turning local pharmacies into clinical hubs, Truentity aims to improve healthcare access in rural areas and provide pharmacies with new, sustainable revenue streams. (Link)
  4. Prescription infrastructure startup Photon secures $16 million in Series A funding led by Healthier Capital, with participation from Notation, Flare Capital, and Evidenced Photon has closed a $16 million Series A funding round to modernize the digital prescription experience for patients and providers. The round was led by Healthier Capital and included participation from Flare Capital and Notation, bringing Photon’s total capital raised to over $25 million. Photon provides an API-driven infrastructure that allows patients to see real-time prescription pricing and stock availability at retail pharmacies. The new funds will support the expansion of Photon’s engineering team and the growth of its commercial partnerships with health systems and digital health brands. By simplifying the prescription routing process, Photon aims to reduce the estimated 20-30% of prescriptions that are currently abandoned by patients. (Link)
  5. AI pathology developer Techcyte bags $15 million in funding led by Van Tuyl Companies, with participation from strategic investors Zoetis Inc. (NYSE: ZTS) and Mayo Clinic. Techcyte has raised $15 million to scale its AI-powered digital pathology platform and drive the company toward profitability. The financing round was led by Van Tuyl Companies and saw continued support from Zoetis (ZTS) and Mayo Clinic. As part of the partnership, Techcyte will leverage Mayo Clinic’s massive dataset of 17 million pathology slides to further train its diagnostic algorithms. The Techcyte Fusion platform is designed to unify human, veterinary, and environmental pathology workflows into a single digital interface. The investment will be used to expand Techcyte’s global footprint and address the critical shortage of laboratory professionals by automating routine and complex diagnostic tasks. (Link)
  6. UnityAI launches its StaffOps platform for outpatient care following an $8.5 million Series A funding round led by Third Prime, with participation from Nashville Capital Network. UnityAI has introduced its AI-powered staffing and operations platform, StaffOps, following an $8.5 million Series A round led by Third Prime. The funding, which included participation from Whistler Capital Partners and Max Ventures, supports the company’s mission to optimize the outpatient healthcare workforce. StaffOps uses agentic AI to handle patient interactions and coordinate clinical tasks, currently managing over 300,000 interactions monthly. UnityAI has already partnered with large groups like Tennessee Oncology to improve clinical throughput and patient access. The new capital will be used to expand UnityAI’s go-to-market team and enhance its EHR integration capabilities, ensuring AI-driven tasks are safe, traceable, and highly efficient for medical staff. (Link)
  7. Specialty clinic automation startup TriFetch raises $1.9 million in pre-seed funding led by Nexus Venture Partners with participation from high-profile angel investors TriFetch has emerged from stealth with $1.9 million in pre-seed capital to develop AI automation tools specifically for independent medical practices. Nexus Venture Partners led the round, which also featured investment from notable angels affiliated with Google and Hippocratic AI. TriFetch’s platform acts as an automation layer that manages administrative tasks like patient scheduling, referral processing, and prior authorizations. Unlike traditional EHRs, TriFetch integrates with existing workflows to reduce the daily “paperwork” burden on clinicians. The funding will be used to build out the core product and expand its reach to more specialty clinics across the U.S., focusing on improving clinic profitability and reducing staff burnout. (Link)
  8. Depth Health raises $1 million in seed funding led by Green Harvest Capital Industries (GHC Industries) to scale its AI-driven hospital throughput optimization platform Depth Health has secured $1 million in seed financing to advance its Augmented Surveillance Intelligence (ASI) platform, which optimizes hospital patient flow and bed management. The funding round was led by Green Harvest Capital Industries, whose CEO, Ankit Patel, will join Depth Health’s Board of Directors. The capital will be used to enhance Depth Health’s explainable AI models, which provide real-time recommendations for patient placement and discharge. By joining the GHC Industries portfolio, Depth Health gains access to a broader ecosystem of clinical intelligence technologies. The investment aims to help hospitals reduce throughput bottlenecks and improve financial performance through data-backed operational efficiency. (Link)
  9. Virchu Sciences secures first institutional funding round to advance AI-powered oncology drug discovery platform Virchu Sciences has closed its first institutional investment round led by the Ohio Innovation Fund, with participation from JobsOhio Ventures and Rev1 Ventures. The Columbus, Ohio-based company operates at the intersection of AI, pharma, biotech, and academic research, developing multimodal AI solutions to accelerate drug discovery, advance treatment identification, and enable precision oncology testing. The new capital will support expansion of its data engineering and AI team, enhancement of its Data Discovery and Delivery Platform, and go-to-market efforts targeting academic institutions and commercial partners. The round underscores strong Ohio ecosystem support for AI-enabled life sciences innovation. (Link) (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update Feb 2nd, 2026

LECO_Weekly-Healthcare-News_2-2-2026Download
  1. Boston Scientific (NYSE: BSX) completes $600M acquisition of Nalu Medical to deepen neuromodulation portfolio for chronic pain The deal adds Nalu’s miniaturized, battery‑free implantable pulse generator for spinal cord and peripheral nerve stimulation, wirelessly powered by an external wearable disc and controlled via smartphone, with an expected 18‑year service life. Nalu’s system, cleared initially by the FDA in 2019 and later for whole‑body MRI use, delivers neuromodulation for chronic neuropathic pain with capabilities comparable to larger IPGs. Boston Scientific projects Nalu revenue above $60 million in 2025 with more than 25% growth in 2026 and expects the transaction to become increasingly accretive to earnings after 2027. (Link)
  2. Laborie acquires JADA System for $465M, backed by Patricia Industries to strengthen its global maternal health and postpartum haemorrhage care portfolio The acquisition brings an FDA-cleared device for rapid control of abnormal postpartum uterine bleeding into Laborie’s comprehensive obstetrics portfolio spanning antepartum through neonatal care. JADA uses low-level vacuum to stimulate natural uterine contractions, helping stop postpartum haemorrhage quickly and effectively and has already been used in more than 136,000 mothers across over 20 countries, supported by multiple safety and effectiveness studies. Laborie will onboard over 90 primarily commercial team members as part of a long-term strategy to back innovations that improve maternal outcomes and support sustainable growth. (Link)
  3. Halozyme Therapeutics acquires Surf Bio for up to $400M to expand hyperconcentration capabilities in subcutaneous drug delivery The transaction, closed in late December 2025 and announced January 28, 2026, includes $300M upfront (subject to adjustments) and up to $100M in development/regulatory milestones. Surf Bio’s platform enables high-concentration formulation of monoclonal antibodies, small molecules, and biologics using spray drying, a novel protective excipient, and polymer-based surface tension reduction for protein stability and low-friction delivery via auto-injector. Complementing Halozyme’s Enhanze hyaluronidase and recent Elektrofi/Hypercon acquisition, the technology extends IP into the mid-2040s, opens non-exclusive partnerships across autoimmune, neurology, nephrology, cardiovascular, nucleic acids, and ADCs, and supports rapid home-administration innovations, positioning Halozyme for durable royalty growth and next-generation delivery leadership. (Link)
  4. Illumina (NASD: LMN) acquires SomaLogic and assets from Standard BioTools for $350 million plus milestones to expand proteomics and multiomics leadership The acquisition strengthens Illumina’s position in the fast-growing proteomics market by integrating SomaLogic’s data-driven protein analysis technologies with Illumina’s next-generation sequencing (NGS) and multiomics solutions. Customers will gain access to enhanced tools, including SomaScan assays, DRAGEN software, and Illumina Connected Multiomics, enabling large-scale, flexible, and cost-efficient analysis of complex biological data. The combination supports faster drug discovery and deeper insights into human health. Illumina will maintain continuity for existing SomaLogic customers while expanding global access to the unified platform, investing in scalable growth and innovation across its sequencing and proteomics ecosystems. (Link)
  5. Sword Health acquires Kaia Health in $285M transaction backed by General Catalyst, Khosla Ventures, Transformation Capital and Founders Fund to scale AI-first MSK and pulmonary care in the U.S. and Germany The transaction adds Kaia’s digital musculoskeletal and pulmonary programs and its coveted position in Germany’s reimbursed digital health pathway, giving access to more than 70 million publicly insured individuals. Sword plans to migrate Kaia’s U.S. members to its own AI Care platform, unifying client relationships while extending a wider range of AI-enabled remote services that blend automation with clinician oversight. The combined organization aims use of AI care manager agents to automate administrative tasks and support more accessible virtual care. (Link)
  6. Premise Health acquires Crossover Health, via its financial sponsors OMERS Private Equity, Ares Management, and Ares Capital Corporation BDC creating unified advanced primary and occupational care company The combined organization will operate nearly 900 onsite, nearsite and virtual wellness centers, serving more than 400 employers, unions, tribes and health plans across the U.S. Its integrated model spans advanced primary care, occupational health, behavioral health, care management and navigation, physical therapy and chiropractic, with Premise’s pharmacy services adding chronic condition support and virtual dispensing. Both companies will continue developing alternative payment models, including a primary‑care‑centered health plan, with leadership from both executive teams retained to drive a shared vision of scalable, team‑based primary care that lowers costs and improves outcomes. (Link)
  7. Spring Health to acquire Alma in deal backed by Generation Investment Management, Tiger Global, Thoma Bravo, Cigna Ventures, Optum Ventures, Insight Partners, Tusk Venture Partners, Primary Venture Partners, and Sound Ventures to build AI-enabled lifelong mental health platform and expand nationwide care access The acquisition unites two major digital mental health innovators, combining Spring Health’s AI-driven precision care platform with Alma’s strong national payer relationships and provider infrastructure. The deal will integrate advanced technology, data-informed personalization, and in-network clinician enablement to improve patient outcomes while easing administrative burdens. Both leverage shared resources to advance quality, accessibility, and value across the evolving mental healthcare ecosystem. (Link)
  8. Resonetics to acquire Resolution Medical in a Carlyle, GTCR and Arcline Investment Management–backed deal to expand neuromodulation and structural heart device capabilities The acquisition will add Resolution Medical’s integrated design, engineering and cleanroom manufacturing capabilities for complex Class II and III devices, significantly deepening Resonetics’ presence in neuromodulation, structural heart and interventional cardiology markets. More than 240 employees, including over 100 engineers, will join Resonetics, enabling it to support customers from early product design and NPI through high‑volume production on a larger global footprint. Both organizations emphasize continuity for existing customers while positioning the combined company as a more comprehensive development and manufacturing partner across the full medical device lifecycle. (Link)
  9. Kodiak Solutions acquires BESLER, via its financial sponsor TPG to strengthen revenue recovery and reimbursement capabilities The acquisition brings BESLER’s revenue integrity tools, including Transfer DRG underpayment detection software and managed reimbursement services, onto Kodiak’s existing analytics and automation platform for hospitals and medical practices. Kodiak aims to give health system CFOs deeper, more actionable insight into net revenue, benchmarking, and reimbursement performance while simplifying complex business office workflows. BESLER’s leadership and subject-matter experts, including former CEO Jonathan Besler, are joining Kodiak to help support more than 2,300 hospitals and 350,000 physicians, while founder Philip Besler retires after four decades building the firm. (Link)
  10. Nuwellis (NASD: NUWE) to acquire Rendiatech to expand real-time kidney function monitoring and advance cardiorenal care portfolio The acquisition advances Nuwellis’ move beyond fluid management into continuous renal diagnostics, enhancing its precision cardiorenal care capabilities. Rendiatech’s Clarity™ system provides automated, continuous urine-output monitoring, offering improved accuracy and efficiency over manual methods. The integration of this technology will support earlier kidney stress detection and data-driven clinical decisions in critical care. Nuwellis plans to use its existing commercial and clinical infrastructure to bring Rendiatech’s innovation to market without new sales channels. The transaction, approved by both companies’ boards, marks a key milestone in establishing a more comprehensive cardiorenal platform once customary closing conditions are met. (Link)
  11. Wisp acquires TBD Health to build women-focused national PrEP and sexual health enterprise and hybrid care platform The deal adds a 50‑state sexual health and diagnostics infrastructure, including routine STI/HIV testing, virtual clinical support and deep partnerships with hospital systems and public health organizations. TBD Health’s TelePrEP and diagnostics capabilities, already integrated with partners like Mount Sinai Health System, San Francisco AIDS Foundation and Planned Parenthood Direct, will underpin Wisp’s move beyond direct‑to‑consumer into enterprise and hybrid care models. Together, the companies plan to close major gaps in preventive sexual health—particularly for women—by offering turnkey PrEP and testing solutions that plug into existing clinical workflows and broaden access across consumer, employer and public health channels. (Link)
  12. NOCD acquires Rebound Health, leveraging Noto AI platform to scale virtual OCD and PTSD specialty care The combined organization will expand virtual, evidence-based therapy for OCD and trauma-related disorders nationwide using Noto, an AI-powered infrastructure that supports payer operations, member identification, enrolment, and clinical workflows. NOCD contributes a large, W‑2-employed therapist network delivering more than 1 million OCD sessions annually, supported by tools like AI-assisted notetaking, outcomes tracking, and peer support between visits. Clinical studies of NOCD’s virtual exposure and response prevention model show meaningful symptom reductions for children and teens, while peer interventions increase engagement, and Noto will now also be used to scale Rebound’s PTSD and complex PTSD services across the U.S. (Link)
  13. Premier Radiology Services to acquire National Radiology Solutions (NRAD) to strengthen nationwide teleradiology network and clinical coverage The merger combines two established teleradiology providers to create a stronger national network with enhanced clinical coverage and streamlined operations. By integrating technological infrastructure, administrative systems, and subspecialty expertise, the unified organization will deliver faster, more accurate diagnostic interpretations. NRAD’s team, including founder Robb Kolb, will join the combined company to ensure seamless service for existing clients. The partnership places emphasis on physician autonomy, innovation, and expanding access to high-quality radiology services. Together, the organizations aim to advance patient care standards and improve efficiency for outpatient healthcare providers across the United States. (Link)
  14. Choice Health at Home to acquire Cy-Fair Health Care and Alliant, via its financial sponsor Trive Capital to expand home health and hospice services across key Southwestern markets The acquisition builds on Choice Health at Home’s strategy to enhance integrated home-based care across key Southwestern markets. Both Cy-Fair Health Care in Texas and Alliant in Colorado bring strong clinical reputations and deep community roots, which will now be supported by Choice Health’s broader operational infrastructure and resources. The move strengthens continuity of care for patients and families, with existing staff retained and services uninterrupted. By combining expertise, technology, and compassionate clinical teams, the expanded organization will improve home health and hospice delivery while advancing Choice Health’s mission to provide accessible, patient-centered care across its seven-state network. (Link)
  15. ncgCARE to acquire Broadstep of North Carolina through Carolina Outreach to expand statewide behavioral health services The acquisition broadens ncgCARE’s community-based behavioral health network across eastern and southeastern North Carolina, reinforcing its commitment to accessible, high-quality mental health and substance use care. Broadstep’s existing staff, leadership, and programs will remain in place, ensuring continuity for patients and families. By integrating Broadstep’s operations into Carolina Outreach, ncgCARE will provide expanded operational, clinical, and compliance support to strengthen long-term sustainability and service delivery. The partnership emphasizes stability, quality, and local engagement while enhancing capacity to meet growing behavioral health needs in communities across Gastonia, Lumberton, Jacksonville, Supply, and Wilmington, North Carolina. (Link)

Venture and Other News  

  1. Vaxcyte prices $550M public offering at $50 per share to fund pneumococcal and infectious disease vaccine pipeline The offering includes 11,000,000 shares with a 30-day underwriter option for up to 1,650,000 additional shares, expecting gross proceeds of $550M (before discounts/expenses), closing February 2, 2026. Proceeds will support clinical advancement of lead next-generation pneumococcal conjugate vaccine VAX-31 (Phase 3 adult/Phase 2 infant), VAX-24, plus prophylactic programs for Group A Strep (VAX-A1) and Shigella (VAX-GI). Leveraging its XpressCF cell-free protein synthesis platform for high-fidelity conjugates, Vaxcyte aims to address serious bacterial diseases with broader, more effective immunizations, accelerating late-stage trials, manufacturing scale-up, and progress toward preventing unmet infectious threats. (Link)
  2. Veradermics and Eikon Therapeutics file for IPOs targeting up to $181M and $318M amid biotech market reopening Veradermics (NYSE: MANE) seeks approximately $181M to advance Phase III VDPHL01 (extended-release oral minoxidil) for pattern hair loss in men and women, supporting approval, commercialization, physician education, brand awareness, supply chain, and infrastructure in dermatology. Eikon Therapeutics (Nasdaq: EIKN), led by former Merck executive Roger Perlmutter, targets up to $318M (with overallotment) primarily for clinical progression of TLR7/8 agonists EIK1001 (melanoma) and EIK1003 (non-small cell lung cancer), plus selective PARP1 inhibitors and WRN helicase assets in challenging oncology indications. The January 2026 filings signal renewed investor confidence post-2025 slowdown, enabling late-stage advancement, pipeline expansion, and public-market capitalization for these high-potential biotechs. (Link)
  3. Cellares raises $257M in Series D round led by Eclipse and BlackRock with participation from T. Rowe Price, Gates Frontier, Duquesne Family Office, Intuitive Ventures, DC Global Ventures and DFJ Growth to scale global cell therapy manufacturing The new funding supports Cellares’ global expansion as it prepares for commercial-scale cell therapy production by 2027. The company will build new manufacturing facilities in the Netherlands and Japan, complementing sites in New Jersey and South San Francisco. Its automated “Cell Shuttle” system enables end-to-end cell therapy production, addressing industry bottlenecks through scalable, high-tech infrastructure. With increasing demand and regulatory validation, Cellares is positioning itself as a leading integrated developer and manufacturer supporting global biopharma partners, including Bristol Myers Squibb. The financing advances its mission to industrialize cell therapy and move toward a public listing. (Link)
  4. Tenpoint Therapeutics raises $235M from Janus Henderson, EQT Nexus, Hillhouse, British Business Bank, EQT Life Sciences, Sofinnova Partners, F-Prime, Eight Roads, Qiming Venture Partners USA, AdBio, Wille, and Hercules Capital to accelerate commercialization of YUVEZZI™ The financing strengthens Tenpoint Therapeutics’ position for the commercial launch of YUVEZZI™, the first FDA-approved dual-agent, once-daily eye drop for presbyopia. The funding includes an $85 million Series B round and a $150 million credit facility, providing the capital needed to scale manufacturing, distribution, and marketing. Tenpoint aims to meet the needs of millions affected by age-related vision decline while delivering a differentiated treatment backed by strong clinical data and safety performance. The company’s leadership is focused on driving YUVEZZI™’s successful rollout and expanding access to innovative ophthalmic solutions. (Link)
  5. Breakthru Medicine emerges from stealth with $60M Series A financing to advance disruptive cancer therapeutics The funding, supported by investors including Dave Morehead (Baylor University endowment), Fred Eshelman (Eshelman Ventures), and Mark Gergen, enables Breakthru Medicine to build its tumor-agnostic platform targeting hard-to-drug cancers through small molecules, next-generation antibody-drug conjugate payloads, and a novel molecular glue approach. The company prioritizes patient-first development by rigorously selecting breakthrough candidates early and eliminating non-viable programs. The capital accelerates pipeline progression and platform expansion to redefine therapeutic possibilities for oncology indications. (Link)
  6. TRexBio raises $50M from Janus Henderson Investors, Alexandria Venture Investments, Avego BioScience Capital, Eli Lilly, Johnson & Johnson Innovation JJDC, Pfizer Ventures and SV Health Investors to advance tissue-targeted Treg immunology pipeline The financing supports TRexBio’s ongoing clinical and preclinical programs focused on tissue-specific regulatory T cell therapies for autoimmune and inflammatory diseases.. Leveraging its Deep Biology Platform, TRexBio maps tissue Treg behavior to uncover novel therapeutic targets. The investment underscores confidence in the company’s precision immunoregulatory approach aimed at delivering more effective, durable treatments for diseases such as atopic dermatitis and other inflammatory disorders. (Link)
  7. Prenosis secures $20M Series A led by PACE Healthcare Capital with UC Investments, UCI Health Ventures, Labcorp Venture Fund, GHIC, Illinois DCEO, and Carle Health, plus $20M BARDA contract to advance AI diagnostics and therapeutics The combined $40 million will drive Prenosis’ development of biology-based, AI-powered diagnostic and therapeutic tools for critical care conditions such as sepsis, ARDS, and acute kidney injury. The BARDA-funded program will include a pivotal clinical trial evaluating an AI-enabled steroid companion diagnostic for severe respiratory infections. These initiatives strengthen Prenosis’ mission to personalize treatment by combining advanced diagnostics with targeted therapeutics, marking a major step in improving outcomes for critically ill patients through precision care. (Link)